{"text": "All efficacy data were analyzed separately for HBeAg - positive and HBeAg - negative patients .Percentage of Participants With Maintained Clinical Response [ Group B : LdT 2301 ] [ Time Frame : 156 weeks , 208 weeks ( from feeder study baseline ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "30.270325"}
{"text": "( 3 )All patients had never received antiviral treatment previously .( 4 ) Intervention : studies directly comparing LAM 100 mg / d plus ADV 10 mg / d and ETV 0.5 mg / d , with a duration more than or equal to 24 weeks .", "label": "", "metadata": {}, "score": "30.585064"}
{"text": "Results .Six eligible trials ( 451 patients in total ) were included in the analysis .The rate of virologic breakthrough in the ETV group was higher than that in the LAM plus ADV group .", "label": "", "metadata": {}, "score": "32.46803"}
{"text": "A study of LDT versus ADV showed that suppression of HBV DNA levels at 24 weeks correlated with efficacy outcomes and viral breakthrough at 1 year [ 36 ] .", "label": "", "metadata": {}, "score": "32.620007"}
{"text": "In addition , all study populations had comparable baseline characteristics between the LAM plus ADV combination and ETV monotherapy groups .Virologic response .The rate of undetectable HBV DNA levels was 72.7 % and 54.5 % in both the ADV add - on LAM group and the ETV group 48 weeks post treatment in the Kim et al .", "label": "", "metadata": {}, "score": "33.30552"}
{"text": "Of these , 20 patients had received a combination of 100 mg of LAM plus 10 mg of ADV per day ( ADV group ) , and 124 patients had received either 100 mg of LAM per day or 0.5 mg of ETV ( non - ADV group ) .", "label": "", "metadata": {}, "score": "33.429184"}
{"text": "Five eligible studies ( 328 patients in total ) were included in the analysis .LAM plus ADV combination therapy produced more rapid HBV DNA reduction rate at 12 weeks than that of ETV monotherapy .", "label": "", "metadata": {}, "score": "33.653893"}
{"text": "An Open Label Trial of Telbivudine ( LdT ) in Adults With Chronic Hepatitis B Previously Treated in Idenix - Sponsored Telbivudine Studies .Percentage of Participants Who Maintained Therapeutic Response [ Group A : LdT Pool 2302/015 ] [ Time Frame : 156 weeks , 208 weeks ( from feeder study baseline ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "33.913116"}
{"text": "Clinical data were collected at baseline , and every 3 months after retreatment .The primary efficacy outcomes were ALT normalization , reduction in HBV DNA , and seroconversion of HBeAg .", "label": "", "metadata": {}, "score": "34.875587"}
{"text": "All efficacy data were analyzed separately for HBeAg - positive and HBeAg - negative patients .Percentage of Participants Who Maintained Therapeutic Response [ Group A : LAM Pool 2302/015 ] [ Time Frame : 52 weeks , 104 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "35.483223"}
{"text": "Virological response .The reduction in serum HBV DNA levels from baseline of retreatment during the first year of observation period was greater in LAM plus ADV than in LAM alone retreatment ( Figure 3 ) .", "label": "", "metadata": {}, "score": "35.54134"}
{"text": "40.1 % in ETV monotherapy ) .Ryu et al .[ 22 ] showed insufficient virologic responses following ADV add - on LAM therapy in patients with higher baseline HBV DNA levels .", "label": "", "metadata": {}, "score": "36.405678"}
{"text": "Among them , 144 consecutive patients who received ADV or the other nucleoside analogues ( LAM or ETV ) for more than 1 year were enrolled .", "label": "", "metadata": {}, "score": "36.431473"}
{"text": "[40 ] reported that at 24 weeks , the rates of HBV DNA negativity in the LAM and ADV combination group were higher than that in the LAM or ADV monotherapy group .", "label": "", "metadata": {}, "score": "37.323498"}
{"text": "-3.7 log 10 copies / ml ) .However , 96 weeks post treatment , significant reductions were observed in the ADV combination group ( -2.4 vs .", "label": "", "metadata": {}, "score": "37.46666"}
{"text": "[26 ] found that the mean reduction in serum HBV DNA at 48 and 72 weeks post treatment was similar between the ETV and ADV combination therapy groups ( -3.1 vs .", "label": "", "metadata": {}, "score": "37.609"}
{"text": "A fixed - effect analysis showed that the HBeAg seroconversion rate in the LAM + ADV group was distinctly higher than that of in ETV group at both 48 and 96 weeks ( 20.9 % vs. 11.8 % , 42.9 % vs. 21.5 % , respectively ) .", "label": "", "metadata": {}, "score": "37.655647"}
{"text": "Two cases had LAM - resistant mutations before onset of therapy ( rtM204I / V \u00b1 rtL180 M ) .Previous studies have confirmed that the presence of rtM204I / V and rtl180 M can reduce the genetic resistance barrier to ETV [ 33 , 34 ] .", "label": "", "metadata": {}, "score": "37.764122"}
{"text": "There were no statistical differences in the virologic response , ALT normalization and HBeAg seroconversion rates in either group 48 weeks post treatment .We speculated that differences in the HBV DNA detection limits , different definitions of baseline levels , regional genotypic difference in HBV isolates , the rate of HBeAg positive and the male to female ration may explain this difference .", "label": "", "metadata": {}, "score": "38.647858"}
{"text": "No evidence of ADV resistance was detected in the 28 patients undergoing ADV add - on LAM combination therapy during a median duration of 40 ( 9 - 53 ) months .", "label": "", "metadata": {}, "score": "39.031406"}
{"text": "Results .Characteristics of the study patients .A total of 53 HBeAg - positive CHB patients were analyzed in the study , which comprised of 25 patients in LAM plus ADV and 28 patients in LAM alone retreatment ( Figure 1 ) .", "label": "", "metadata": {}, "score": "39.58199"}
{"text": "A multi - center randomized active - controlled open - label trial .Patients will be randomly assigned 1:1 to receive tenofovir ( 300 mg / day ) or tenofovir ( 300 mg / day ) plus entecavir ( 1 mg / day ) for 48 weeks .", "label": "", "metadata": {}, "score": "39.730106"}
{"text": "Only 3 studies examined in this analysis reported HBeAg seroconversion rates 48 weeks post treatment [ 21 , 24 , 27 ] .The rate of HBeAg seroconversion was higher in the LAM plus ADV combination therapy group than that observed for patients in the ETV group described by Kim et al .", "label": "", "metadata": {}, "score": "39.800858"}
{"text": "Percentage of Participants With Sustained Therapeutic Response [ Group C : LdT Pool and LAM Pool ( 2302/015 ) ] [ Time Frame : 52 weeks,104 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "39.845184"}
{"text": "LAM plus ADV combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to ETV monotherapy .HBV DNA baseline levels and the initial virologic response ( IVR ) were predictive of the virologic response .", "label": "", "metadata": {}, "score": "40.667816"}
{"text": "No ALT flares were recorded after either switching to or adding on ADV to LAM .Therapeutic efficacy , in terms of undetectable HBV - DNA and ALT normalization in the first 12 months of ADV therapy , was similar between the 2 regimens .", "label": "", "metadata": {}, "score": "40.770172"}
{"text": "Methods .This is a prospective controlled study , and a total of 53 hepatitis B e antigen ( HBeAg)-positive patients with viral rebound but without resistance were received either LAM plus ADV or LAM alone treatment .", "label": "", "metadata": {}, "score": "40.789177"}
{"text": "Yu et al .In another study , Jayakumar et al .[ 23 ] found that the median decrease in HBV DNA levels in a combination group were 92.73 % and 99.57 % at 12 and 24 weeks of therapy , respectively ( considering the baseline HBV DNA levels to be 100 % ) .", "label": "", "metadata": {}, "score": "41.00531"}
{"text": "Furthermore , the results of the analysis prove that LAM plus ADV combination therapy produced more rapid and significant reduction in HBV DNA levels at 12 weeks of therapy , compared with ETV monotherapy , even though there was no significant difference observed at 96 weeks post - treatment .", "label": "", "metadata": {}, "score": "41.231125"}
{"text": "Effect of LAM + ADV vs .ETV on HBeAg seroconversion 48 weeks post treatment .Factors predicting the virologic response .Two studies described factors predictive of the virologic response in the different treatment groups [ 21 , 22 ] .", "label": "", "metadata": {}, "score": "41.515316"}
{"text": "Effect of LAM + ADV vs .ETV on virologic response 48 weeks post treatment .Mean HBV DNA reduction levels .Heterogeneity was assessed and not found to be significant 24 weeks post treatment .", "label": "", "metadata": {}, "score": "41.541992"}
{"text": "A study evaluating long - term ADV therapy reported that 5 % of the patients who received therapy up to 5 years had a slight elevation in serum creatinine concentration [ 24 ] .", "label": "", "metadata": {}, "score": "41.587425"}
{"text": "19 Studies are needed to explore whether the duration of continuing LAM during ADV therapy can be shortened to terminate LAM resistance earlier but still be able to prevent resistance to the add - on agent .", "label": "", "metadata": {}, "score": "42.01681"}
{"text": "ETV on the mean reduction of HBV DNA 24 weeks post treatment .Biochemical response .The ALT normalization rates were 74.3 % and 75.0 % for patients in the ADV add - on LAM group and ETV groups ; respectively , 24 weeks post treatment in the Kim et al .", "label": "", "metadata": {}, "score": "42.024143"}
{"text": "All efficacy data were analyzed separately for HBeAg - positive and HBeAg - negative patients .Percentage of Participants Who Maintained Therapeutic Response [ Group A : Feeder Studies 2401/2402/010 ] [ Time Frame : 52 weeks , 104 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "42.286976"}
{"text": "All efficacy data were analyzed separately for HBeAg - positive and HBeAg - negative patients .Percentage of Participants With Sustained Therapeutic Response [ Group C : Other Feeder Studies ] [ Time Frame : 52 weeks,104 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "42.325962"}
{"text": "Although the number of patients in this study was relatively small , the randomized controlled study design and sufficiently long and careful follow - up evaluations provide solid evidence supporting the notion that ADV add - on LAM combination therapy prevents or delays ADV resistance .", "label": "", "metadata": {}, "score": "42.404373"}
{"text": "After 48 weeks all subjects will receive open - label TDF , and the efficacy and safety of TDF will continue to be monitored for the remainder of the study .", "label": "", "metadata": {}, "score": "42.71281"}
{"text": "A participant was a nonresponder for the primary endpoint if either biopsy ( baseline or end - of - treatment ) was missing or if there was not an HBV DNA value available at or beyond Week 40 .", "label": "", "metadata": {}, "score": "43.087383"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .515 were randomized 1:1 to treatment arms A and B. .", "label": "", "metadata": {}, "score": "43.16745"}
{"text": "Only three studies [ 22 , 24 , 25 ] reported virologic responses at 96 weeks .Therefore , a random - effect approach was used which indicated that the virologic response was higher in the combination therapy group than that in the ETV monotherapy group ( 96.2 % vs. 82.8 % ) .", "label": "", "metadata": {}, "score": "43.174942"}
{"text": "Patients will be screened within 4 weeks before randomization to determine study eligibility .Study Type ICMJE .Interventional .Study Phase .Phase 4 .", "label": "", "metadata": {}, "score": "43.46866"}
{"text": "Patients .Study design .This is a prospective controlled study , aimed to evaluate and compare the efficacy of LAM plus ADV with that of LAM alone retreatment in patients with viral relapse after cessation of LAM antiviral therapy .", "label": "", "metadata": {}, "score": "43.679356"}
{"text": "[ 24 ] reported that the ADV combination group had a significant reduction in HBV DNA levels compared to the ETV treatment group 24 weeks post treatment [ -4.17 vs .", "label": "", "metadata": {}, "score": "43.773212"}
{"text": "ADV - based therapies have been shown to be efficacious and safe for up to 5 years in HBeAg positive and negative patients [ 10 , 11 ] .", "label": "", "metadata": {}, "score": "44.11757"}
{"text": "LAM was the first drug to have been approved and has been used extensively for more than a decade with an excellent safety record .However , LAM resistance has become a serious clinical challenge because its incidence increases with increasing duration of therapy , and it is associated with virologic / biochemical breakthrough , hepatitis flare , and even hepatic decompensation or mortality . 1 ADV and ETV are associated with a delayed and low incidence of resistance in treatment - na\u00efve patients ; both drugs have antiviral activity against LAM - resistant HBV , although ETV displays some level of cross - resistance .", "label": "", "metadata": {}, "score": "44.196964"}
{"text": "Insufficient antiviral efficacy caused by drug resistance has resulted in attenuated viral suppression that may lead to significant clinical deterioration [ 9 , 30 ] .", "label": "", "metadata": {}, "score": "44.42835"}
{"text": "Percentage of Participants With Maintained Clinical Response [ Group B : LAM 2301 ] [ Time Frame : 52 weeks,104 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "44.918777"}
{"text": "All blood samples were obtained from patients after fasting .The nearest available match on the estimated propensity score was used to select participants in the ADV group and find participants in the non - ADV group with the closest propensity scores .", "label": "", "metadata": {}, "score": "44.991905"}
{"text": "The proportion of patients who achieve complete virologic response ( serum HBV DNA concentrations below 15 IU / mL ) .Original Secondary Outcome Measures ICMJE ( submitted : July 10 , 2012 ) .", "label": "", "metadata": {}, "score": "45.16911"}
{"text": "Patients will take both telbivudine and HAART for 24 weeks .At Week 48 , patients will discontinue telbivudine and continue on the HAART regimen alone for an additional 12 weeks .", "label": "", "metadata": {}, "score": "45.569714"}
{"text": "This notion is supported by a study showing the superiority of 300 mg tenofovir treatments , another acyclic nucleotide analog , to 10 mg ADV in patients with LAM resistance .", "label": "", "metadata": {}, "score": "45.720715"}
{"text": "9 Shortly afterward , the alarming problem of ADV resistance emerged .Case series studies have shown that , compared with LAM - na\u00efve patients , ADV resistance occurs earlier and more frequently ( up to 18 % at 48 weeks and 25 % at 24 months ) in patients with LAM resistance who were switched to ADV monotherapy .", "label": "", "metadata": {}, "score": "45.83144"}
{"text": "Another two patients developed viral breakthrough as mentioned in the Zhang et al .[ 24 ] study .One patient had ETV resistance mutations ( rtL180 M + T184L + M204V ) , and the other had S202G / I and M204V mutations .", "label": "", "metadata": {}, "score": "45.89448"}
{"text": "Virological response rates of patients receiving ADV+LAM or LAM alone during the first year of retreatment .HBeAg response .HBeAg loss and seroconversion rates of patients receiving ADV+LAM or LAM alone during the first year of retreatment .", "label": "", "metadata": {}, "score": "45.897926"}
{"text": "Safety .Majority of patients were well tolerated in two retreatment groups .Among patients receiving LAM plus ADV , only1 patient had serum creatinine slightly increasing but there was no discontinuation due to this adverse event .", "label": "", "metadata": {}, "score": "46.09942"}
{"text": "1077 - 1082 , 2008 .View at Google Scholar \u00b7 View at Scopus . Y. Suzuki , F. Suzuki , Y. Kawamura et al . , \" Efficacy of entecavir treatment for lamivudine - resistant hepatitis B over 3 years : histological improvement or entecavir resistance ? \"", "label": "", "metadata": {}, "score": "46.300034"}
{"text": "4 , pp .327 - 333 , 1999 .View at Google Scholar \u00b7 View at Scopus .S. J. Hadziyannis , N. C. Tassopoulos , E. J. Heathcote et al . , \" Long - term therapy with adefovir dipivoxil for HBeAg - negative chronic hepatitis B for up to 5 years , \" Gastroenterology , vol .", "label": "", "metadata": {}, "score": "46.55211"}
{"text": "The other reports were on cohort studies with defined inclusion and exclusion criteria and definitions of the treatment responses .All study populations had comparable baseline characteristics between the LAM + ADV and ETV groups .", "label": "", "metadata": {}, "score": "46.898617"}
{"text": "HIV Infections .Hepatitis B .Intervention ICMJE .Drug : Telbivudine .Administered orally at a daily dosage of 600 mg for a period of 48 weeks .", "label": "", "metadata": {}, "score": "46.998688"}
{"text": "These findings indicated that combination of LAM plus ADV would be a good option for the retreatment of CHB patients with viral relapse after cessation of LAM .", "label": "", "metadata": {}, "score": "47.190063"}
{"text": "Studies indicate that 70 % to 80 % of HIV infected patients have or have had HBV infection and that 10 % are HBV carriers .", "label": "", "metadata": {}, "score": "47.227905"}
{"text": "11 , pp .1317 - 1325 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Yatsuji , F. Suzuki , H. Sezaki et al . , \" Low risk of adefovir resistance in lamivudine - resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy : two - year follow - up , \" Journal of Hepatology , vol .", "label": "", "metadata": {}, "score": "47.35333"}
{"text": "At present , combination therapy with ADV and LAM must be continued for a long period of time , even though long - term use of ADV is associated with a slight risk of renal toxicity [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "47.50255"}
{"text": "At Week 24 , patients will add a HAART regimen containing lamivudine and efavirenz plus either didanosine or abacavir .Patients who are unable to add a HAART regimen at Week 24 due to lab abnormalities or other contraindications will be allowed to delay the initiation of HAART until Week 30 .", "label": "", "metadata": {}, "score": "47.54876"}
{"text": "Efficacy measures .The rates of biochemical response , virologic response , and HBeAg seroconversion were used as primary efficacy measures .Emergence of viral resistance and the safety profiles were used as secondary efficacy measures .", "label": "", "metadata": {}, "score": "47.565903"}
{"text": "However , more than 60 % of patients with chronic HBV infection who receive long - term LAM therapy become resistant to the agent within 4 years of starting the therapy [ 7 ] .", "label": "", "metadata": {}, "score": "47.698975"}
{"text": "After 1 year retreatment , the proportion of undetectable HBV DNA was achieved in 80 % of patients receiving LAM plus ADV as compared to 42.9 % of patients receiving LAM alone .", "label": "", "metadata": {}, "score": "47.729996"}
{"text": "Reporting Groups .Description .Arm A : LPV / r Plus RAL .Participants were administered LPV / r plus RAL orally twice daily .", "label": "", "metadata": {}, "score": "47.75718"}
{"text": "Study Arm ( s ) .Experimental : TDF - TDF .TDF plus placebo to match ADV ( double - blind period ) , followed by TDF ( open - label period ) .", "label": "", "metadata": {}, "score": "48.638466"}
{"text": "PubMed View Article .Gerolami R , Bourliere M , Colson P , Halfon P , Borentain P , Henry M , Botta D , Thibault V , Khiri H , Tamalet C : Unusual selection of rtA181V HBV mutants cross - resistant to adefovir following prolonged lamivudine monotherapy : report of two cases .", "label": "", "metadata": {}, "score": "48.6987"}
{"text": "However , because the criteria for discontinuation of nucleos(t)ide analogue therapy are not clear , long - term ADV plus LAM combination therapy is required in these patients to avoid risk of relapse .", "label": "", "metadata": {}, "score": "48.880375"}
{"text": "Three had genetic mutations conferring to ETV ( two had rtL180 M , T184L and M204I mutations ; one had rtL180 M and M204V LAM - resistance mutations ) .", "label": "", "metadata": {}, "score": "48.90309"}
{"text": "Add - on ADV rescue therapy could be maintained for LAM - resistant patients with lower viral loads at baseline and IVR 24 weeks post antiviral treatment .", "label": "", "metadata": {}, "score": "48.96346"}
{"text": "5 , pp .1445- 1451 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Yatsuji , F. Suzuki , H. Sezaki et al . , \" Low risk of adefovir resistance in lamivudine - resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy : two - year follow - up , \" Journal of Hepatology , vol .", "label": "", "metadata": {}, "score": "49.1246"}
{"text": "To Longitudinally Assess the Clinical Efficacy of Longer - term Treatment With Telbivudine [ Time Frame : 52 weeks , 104 weeks , 156 weeks , 208 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "49.255665"}
{"text": "J Viral Hepat 2010 , 17 : 59 - 65 .View Article PubMed .He Z , Wang J , Liu K , Huang H , Du Y , Lin Z , Cai M , Feng X : Randomized trial of lamivudine , adefovir , and the combination in HBeAg - positive chronic hepatitis B. Clin Res Hepatol Gastroenterol 2012 , 36 : 592 - 597 .", "label": "", "metadata": {}, "score": "49.385025"}
{"text": "November 2009 ( Final data collection date for primary outcome measure ) .Intervention Details : .Telbivudine was to be supplied as white to off - white , oval , bi - convex tablets for the 200 mg tablets and white to off - white ovaloid , slightly curved , beveled edges , film coated tablets for the 600 mg tablets .", "label": "", "metadata": {}, "score": "49.441025"}
{"text": "Arm B : LPV / r Plus Best Available NRTIs .Participants were administered LPV / r orally twice daily , plus NRTI options provided by the study , to include the best available NRTIs .", "label": "", "metadata": {}, "score": "49.478096"}
{"text": "LAM was selected for study due to the abundant clinical experience and lowest cost .Evidence - based medicine identified that combination therapy could reduce drug - associated resistance to ensure long - term therapy [ 11 ] , especially , for LAM resistant and liver transplanted patients [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "49.576775"}
{"text": "In our study , patients receiving combination therapy of LAM and ADV were well tolerated , and no viral breakthrough was reported and no LAM- or ADV - associated resistant strains were detected .", "label": "", "metadata": {}, "score": "49.595055"}
{"text": "Biochemical response .Serum ALT levels declined in both treatment groups , but ALT level was normalized in a higher proportion of LAM plus ADV than LAM alone retreatment in total .", "label": "", "metadata": {}, "score": "49.714626"}
{"text": "Thus , the de novo combination LAM and ADV were expected to achieve a better outcome than that in ETV monotherapy in terms of multidrug resistance .", "label": "", "metadata": {}, "score": "49.76174"}
{"text": "Of note is that the study by Rapti et al .14 enrolled patients with virological and biochemical breakthrough .Thus , the efficacy in terms of decline of serum HBV - DNA to undetectable level by sensitive PCR assay is insufficient even in patients who received combination therapy , as was demonstrated in earlier case series studies .", "label": "", "metadata": {}, "score": "49.782772"}
{"text": "Compared to CHB patients resistant to LAM alone in our study ( regardless of combination therapy or monotherapy ) , the rate of virologic response was lower ( 16.7 % vs .", "label": "", "metadata": {}, "score": "49.783882"}
{"text": "Zhonghua Gan Zang Bing Za Zhi 2011 , 19 : 88 - 92 .PubMed .Jayakumar R , Joshi YK , Singh S : Laboratory evaluation of three regimens of treatment of chronic hepatitis B : tenofovir , entecavir and combination of lamivudine and adefovir .", "label": "", "metadata": {}, "score": "50.142635"}
{"text": "Four studies [ 21 , 23 , 25 ] showed the biochemical response rates at weeks 12 , and 24 .The fixed - effect approach was used .", "label": "", "metadata": {}, "score": "50.25619"}
{"text": "Patients ' treatment information before randomization will be retrospectively collected .( DNA change , HBeAg status , HBsAg titre , ALT , and treatment duration .", "label": "", "metadata": {}, "score": "50.30652"}
{"text": "[ Time Frame : Baseline ; Weeks 145 to 192 ] [ Designated as safety issue : No ] .Number of Participants With HBV Genotypic Changes From Baseline at Week 240 ( Resistance Surveillance )", "label": "", "metadata": {}, "score": "50.310146"}
{"text": "Description .Arm A : LPV / r Plus RAL .Participants were administered LPV / r plus RAL orally twice daily .Lopinavir / ritonavir : Lopinavir 400mg / ritonavir 100 mg orally twice daily .", "label": "", "metadata": {}, "score": "50.36757"}
{"text": "902 - 911 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Lampertico , M. Vigan\u00f2 , E. Manenti , M. Iavarone , E. Sablon , and M. Colombo , \" Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine - resistant hepatitis B patients , \" Gastroenterology , vol .", "label": "", "metadata": {}, "score": "50.40322"}
{"text": "Number of Participants With HBV Genotypic Changes From Baseline at Week 288 ( Resistance Surveillance )[ Time Frame : Baseline ; Weeks 241 to 288 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "50.44617"}
{"text": "Some problems associated with ADV add - on LAM combination therapy deserve attention .It has been shown that maintained LAM therapy provides a continuing selective advantage to a LAM - resistant strain over wild - type HBV and that LAM - resistant HBV may persist in the majority of patients after 1 year of ADV add - on LAM combination therapy .", "label": "", "metadata": {}, "score": "50.63521"}
{"text": "No viral resistance occurred in combination therapy and six patients in ETV group were experienced with viral breakthrough .Both groups were well tolerated .Conclusion .", "label": "", "metadata": {}, "score": "50.642746"}
{"text": "With prolonged durations of the combination treatment , not only effects , but also costs should be evaluated .Wu et al .[42 ] observed that the initiation of rescue therapies for LAM - resistant CHB with adding ADV is likely to be more cost - effective than ADV , ETV , TDF monotherapy .", "label": "", "metadata": {}, "score": "50.701717"}
{"text": "The purpose of the study described here was to systematically review and meta - analyze all published studies designed to treat CHB naive patients with LAM plus ADV therapy and compare it with ETV monotherapy in terms of efficacy and viral resistance .", "label": "", "metadata": {}, "score": "50.799522"}
{"text": "10.1097/MOG.0b013e32835ff1e9 View Article PubMed .Angus PW , Patterson SJ , Strasser SI , McCaughan GW , Gane E : A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post - liver transplantation hepatitis B prophylaxis .", "label": "", "metadata": {}, "score": "50.88963"}
{"text": "10.1016/j.jhep.2010.03.020 View Article PubMed .Kim SS , Cho SW , Kim SO , Hong SP , Cheong JY : Multidrug - resistant hepatitis B virus resulting from sequential monotherapy with lamivudine , adefovir , and entecavir : clonal evolution during lamivudine plus adefovir therapy .", "label": "", "metadata": {}, "score": "50.946278"}
{"text": "A history of treated malignancy ( other than hepatocellular carcinoma ) is allowable if the patient 's malignancy has been in complete remission , off chemotherapy and without additional surgical intervention , during the preceding three years .", "label": "", "metadata": {}, "score": "50.964462"}
{"text": "Number of Participants With HBV Genotypic Changes From Baseline at Week 144 ( Resistance Surveillance )[ Time Frame : Baseline ; Weeks 97 to 144 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "50.980827"}
{"text": "In fact , a wealth of clinical experience also suggested the problem of viral relapse after drug withdrawal could not be ignored [ 7 - 9 ] .", "label": "", "metadata": {}, "score": "51.09749"}
{"text": "To enroll in this study , patients must not be taking any anti - HIV drugs and can not have taken more than 31 days of treatment with lamivudine ( 3TC ) , protease inhibitors ( PIs ) , or nonnucleoside reverse transcriptase inhibitors ( NNRTIs ) .", "label": "", "metadata": {}, "score": "51.119873"}
{"text": "Tenofovir administered 300 mg daily appears to be superior to ADV administered 10 mg daily in suppressing LAM - resistant strain HBV , and no tenofovir resistance has been detected .", "label": "", "metadata": {}, "score": "51.27247"}
{"text": "On the other hand , some studies reported that not only did the de novo LAM plus ADV combination reduce HBV - DNA detectability , enhance ALT normalization and HBeAg seroconversion , but no cases of genotypic resistance had occurred [ 20 ] .", "label": "", "metadata": {}, "score": "51.475117"}
{"text": "[ 22 ] reported one patient in the ETV monotherapy group had Scr elevated to 48 mol / L. The abnormal values were remained within normal limits during the period of treatment without receiving any additional treatment or adjustment of dosage .", "label": "", "metadata": {}, "score": "51.708786"}
{"text": "As a rescue therapy , LAM plus ADV combination therapy is superior to ADV monotherapy , resulting in effective viral suppression and a reduced risk of developing genotypic resistance [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "51.825054"}
{"text": "However , this hypothesis was recently questioned by clinicians .Thus , it is not difficult to conclude that before the drug - resistance strains reach a high number , they may not be detected in patients with viral relapse after cessation of antiviral treatment [ 16 ] .", "label": "", "metadata": {}, "score": "51.892143"}
{"text": "307 - 313 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. J. Tenney , R. E. Rose , C. J. Baldick et al . , \" Two - year assessment of entecavir resistance in lamivudine - refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present , \" Antimicrobial Agents and Chemotherapy , vol .", "label": "", "metadata": {}, "score": "51.936962"}
{"text": "1 The study by Rapti et al .14 has also shown that a LAM - resistant strain may persist up to 36 months in patients on combination therapy , and is a possible reason for suboptimal viral response .", "label": "", "metadata": {}, "score": "51.969376"}
{"text": "A Multicenter Randomized Controlled Open - label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment .", "label": "", "metadata": {}, "score": "52.049324"}
{"text": "However , considering the practical benefits and limitations of ADV therapy , individualized treatment regimens need to be implemented in treating patients with a history of prior LAM resistance .", "label": "", "metadata": {}, "score": "52.104057"}
{"text": "HBeAg response was defined as a loss or seroconversion of HBeAg in patients who were initially HBeAg positive .Viral relapse was defined as an increase in serum HBV DNA to detectable level after achieving virological response .", "label": "", "metadata": {}, "score": "52.106766"}
{"text": "However , because of the limited sample size and short observation time , we currently can not conclude that the combination of ADV plus LAM could increase the rate of HBeAg seroconversion as compared to single nucleoside or nucleotide analogue .", "label": "", "metadata": {}, "score": "52.11003"}
{"text": "The lack of cross - resistance has provided a rationale for the combination of LAM and ADV therapy , which may be the main reason why viral breakthough in the combination group was not observed in the study .", "label": "", "metadata": {}, "score": "52.28071"}
{"text": "Data were not included in the meta - analysis if we could not gain sufficient statistical information .Efficacy measures .The primary efficacy end point was virologic response , defined as the proportion of patients with undetectable HBV DNA levels .", "label": "", "metadata": {}, "score": "52.414383"}
{"text": "Brief Summary .Detailed Description .The efficacy of TDF versus ADV will be evaluated for histologic improvement , reductions in serum hepatitis B virus deoxyribonucleic acid ( HBV DNA ) , changes in liver enzymes , and the generation of antibody to the virus .", "label": "", "metadata": {}, "score": "52.498825"}
{"text": "Antiviral resistance was analyzed using PCR sequencing assay if HBV DNA no less than 1000 copies / mL after 1-year antiviral treatment .Definition .", "label": "", "metadata": {}, "score": "52.53301"}
{"text": "Reijnders JG , Perquin MJ , Zhang N , Hansen BE , Janssen HL : Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010 , 139 : 491 - 498 .", "label": "", "metadata": {}, "score": "52.698154"}
{"text": "Negative serum \u03b2 - human chorionic gonadotropin ( hCG ) .Nucleotide naive , ie , no prior nucleotide ( TDF or ADV ) therapy for greater than 12 weeks .", "label": "", "metadata": {}, "score": "52.720314"}
{"text": "12 , pp .1315 - 1341 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C.-H. Chen , C.-M. Lee , S.-N. Lu et al . , \" Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants , \" Journal of Hepatology , vol .", "label": "", "metadata": {}, "score": "52.77996"}
{"text": "No viral breakthrough was reported in the combination group .However , six patients experienced viral breakthrough in ETV group .Four patients reported in the study by Yu et al .", "label": "", "metadata": {}, "score": "52.819016"}
{"text": "A decrease of 1 point or more indicated improvement , and an increase of 1 point or more indicated worsening .Ranked Assessment of Necroinflammation and Fibrosis at Week 240 [ Time Frame : Baseline ; Week 240 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "52.875183"}
{"text": "If ETV - resistance mutations are present , LAM + ADV combination therapy may be a better choice than ETV in terms of avoiding drug resistence .", "label": "", "metadata": {}, "score": "52.949127"}
{"text": "The aim of this study was to evaluate the effectiveness and resistance of de novo combination of lamivudine ( LAM ) and adefovir dipivoxil ( ADV ) compared with entecavir ( ETV ) monotherapy for nucleos(t)ide - naive patients with CHB .", "label": "", "metadata": {}, "score": "52.960953"}
{"text": "PubMed View Article .Lampertico P , Vigano M , Manenti E , Iavarone M , Sablon E , Colombo M : Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine - resistant hepatitis B patients .", "label": "", "metadata": {}, "score": "53.030724"}
{"text": "Changes in serum HBV DNA levels during 48 weeks of treatment .Proportion of patients with normal ALT [ Time Frame : at 48 weeks of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.17063"}
{"text": "Much less is known about the efficacy of LAM plus ADV combination therapy versus a switch to ETV monotherapy as a rescue for CHB patients resistant to LAM .", "label": "", "metadata": {}, "score": "53.216133"}
{"text": "6 , pp .1743 - 1751 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Gara , X. Zhao , M. T. Collins et al . , \" Renal tubular dysfunction during long - term adefovir or tenofovir therapy in chronic hepatitis B , \" Alimentary Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "53.230637"}
{"text": "The cumulative probability of genotypic ETV resistance developing over 5 years was 51 % in LAM resistant patients [ 17 ] .Studies also have shown that add - on ADV therapy for CHB patients with LAM resistance led to effective viral suppression [ 12 , 13 , 35 ] and patients receiving add - on ADV had a lower risk of developing genotypic resistance [ 12 , 13 , 35 ] .", "label": "", "metadata": {}, "score": "53.37383"}
{"text": "6 , pp .923 - 931 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. L. Hartono , M. O. Aung , Y. Y. Dan , et al . , \" Resolution of adefovir - related nephrotoxicity by adefovir dose - reduction in patients with chronic hepatitis B , \" Alimentary Pharmacology & Therapeutics , vol .", "label": "", "metadata": {}, "score": "53.444157"}
{"text": "PubMed View Article .Ijaz S , Arnold C , Dervisevic S , Mechurova J , Tatman N , Tedder RS , Naoumov NV : Dynamics of lamivudine - resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy .", "label": "", "metadata": {}, "score": "53.501488"}
{"text": "PubMed View Article .J Hepatol 2009 , 50 : 289 - 295 .PubMed View Article .Dienstag JL , Cianciara J , Karayalcin S , Kowdley KV , Willems B , Plisek S , Woessner M , Gardner S , Schiff E : Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003 , 37 : 748 - 755 .", "label": "", "metadata": {}, "score": "53.53142"}
{"text": "[ Time Frame : Baseline ; Weeks 289 to 336 ] [ Designated as safety issue : No ] .Number of Participants With HBV Genotypic Changes From Baseline at Week 384 ( Resistance Surveillance )", "label": "", "metadata": {}, "score": "53.639263"}
{"text": "Those findings gave us another hint that the combination of LAM plus ADV was associated with lower antiviral resistance compared with LAM alone .At present , majority of clinical studies on LAM plus ADV combination therapy were for HBeAg - negative patients , and few studies on HBeAg - positive patients reported the combination of these agents had no synergistic on HBeAg seroconversion .", "label": "", "metadata": {}, "score": "53.65277"}
{"text": "800 - 807 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. J. Hadziyannis , N. C. Tassopoulos , E. Jenny Heathcote et al . , \" Long - term therapy with adefovir dipivoxil for HBeAg - negative chronic hepatitis B , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "53.960144"}
{"text": "Short - term treatment was associated with fewer side effects following combination therapy in our study .This systematic review carried out in this report had some limitations .", "label": "", "metadata": {}, "score": "54.03091"}
{"text": "PubMed View Article .Rapti I , Dimou E , Mitsoula P , Hadziyannis SJ : Adding - on versus switching - to adefovir therapy in lamivudine - resistant HBeAg - negative chronic hepatitis B. Hepatology 2007 , 45 ( 2 ) : 307 - 313 .", "label": "", "metadata": {}, "score": "54.06131"}
{"text": "Evidence - based medicine has demonstrated that effective antiviral treatment of CHB reduced the risk of long - term complications and improved patient survival [ 6 , 7 ] .", "label": "", "metadata": {}, "score": "54.161987"}
{"text": "The purpose of the study described here was to systematically review and meta - analyze all published drug - based studies designed to treat CHB patients with LAM resistance and the use of LAM add - on ADV combination therapy ( or ETV monotherapy ) for the treatment of disease .", "label": "", "metadata": {}, "score": "54.410603"}
{"text": "PubMed View Article .Sanchez MJ , Buti M , Homs M , Palacios A , Rodriguez - Frias F , Esteban R : Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab .", "label": "", "metadata": {}, "score": "54.42289"}
{"text": "Chen EQ , Wang LC , Lei J , Xu L , Tang H : Meta - analysis : adefovir dipivoxil in combination with lamivudine in patients with lamivudine - resistant hepatitis B virus .", "label": "", "metadata": {}, "score": "54.576527"}
{"text": "Received any nucleoside , nucleotide ( TDF or ADV ) or interferon ( pegylated or not ) therapy within 6 months prior to the pre treatment biopsy .", "label": "", "metadata": {}, "score": "54.667175"}
{"text": "Proportion of patients with virologic breakthrough [ Time Frame : at week 48 , 96 , 144 , and 240 of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "54.682865"}
{"text": "HEPATOLOGY 2005 ; 42 : 1414 - 1419 .14 Rapti I , Dimou E , Mitsoula P , Hadziyannis SJ .Adding - on versus switching to adefovir therapy in lamivudine resistant HB e antigen - negative chronic hepatitis B .", "label": "", "metadata": {}, "score": "54.84358"}
{"text": "J Hepatol 2008 , 48 ( 6 ) : 923 - 931 .PubMed View Article .Heo NY , Lim YS , Lee HC , Chung YH , Lee YS , Suh DJ : Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir .", "label": "", "metadata": {}, "score": "54.994576"}
{"text": "Unfortunately , there is no consensus on the retreatment of viral relapse with or without resistance after cessation of nucleos(t)ide analogs treatment .And it is still unknown whether there is significant difference between original drug monotherapy or combined with other drugs without cross - resistance .", "label": "", "metadata": {}, "score": "55.008385"}
{"text": "Interventions : .Drug : TDF .Active Comparator : ADV - TDF .ADV plus placebo to match TDF ( double - blind period ) , followed by TDF ( open - label period ) .", "label": "", "metadata": {}, "score": "55.292614"}
{"text": "PubMed View Article .Hepatology 2008 , 48 ( 1 ) : 99 - 108 .PubMed View Article .Suzuki F , Toyoda J , Katano Y , Sata M , Moriyama M , Imazeki F , Kage M , Seriu T , Omata M , Kumada H : Efficacy and safety of entecavir in lamivudine - refractory patients with chronic hepatitis B : randomized controlled trial in Japanese patients .", "label": "", "metadata": {}, "score": "55.315258"}
{"text": "Tohoku J Exp Med 2007 , 213 : 181 - 186 .10.1620/tjem.213.181 View Article PubMed .Yuen MF , Sablon E , Hui CK , Yuan HJ , Decraemer H , Lai CL : Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy .", "label": "", "metadata": {}, "score": "55.37098"}
{"text": "Between two groups , none hepatocellular carcinoma was reported .Discussion .Thus , it is necessary for us to concern about the re - treatment issues of patients with viral relapse after discontinuation of LAM monotherapy .", "label": "", "metadata": {}, "score": "55.481544"}
{"text": "Characteristics of 19 Well - Matched Pairs in the ADV and Non - ADV Groups .The baseline characteristics of the 144 patients enrolled in the study are summarized in Table 1 .", "label": "", "metadata": {}, "score": "55.667206"}
{"text": "The rate of emergence of viral resistance in the combination group was less than that in the ETV monotherapy .Keywords .Adefovir dipivoxil Combination De novo Entecavir Lamivudine Naive .", "label": "", "metadata": {}, "score": "55.71038"}
{"text": "The purpose of the treatment is to suppress HBV replication and to prevent mortality associated with disease progression to end - stage liver disease and major complications [ 4 , 5 ] .", "label": "", "metadata": {}, "score": "55.75687"}
{"text": "Biochemical response , hepatitis B e antigen seroconversion , and viroligic response were extracted and combined to obtain an integrated result .Viral resistance and safety were reviewed .", "label": "", "metadata": {}, "score": "55.761166"}
{"text": "PubMed View Article .Vigano M , Lampertico P , Iavarone M : High risk of renal impairment during long - term adefovir and lamivudine combination therapy in patients with lamivudine - resistant chronic hepatitis B. J Hepatol 2009 , 50 : S338 - 339 .", "label": "", "metadata": {}, "score": "55.787888"}
{"text": "AST : . aspartate aminotransferase .RCTs : . randomized controlled trials .NA : .nucleos(t)ide analogues .IVR : . initial virologic response .", "label": "", "metadata": {}, "score": "55.795494"}
{"text": "Gastroenterology 2006 , 131 ( 6 ) : 1743 - 1751 .PubMed View Article .PubMed View Article .Gaia S , Barbon V , Smedile A , Olivero A , Carenzi S , Lagget M , Alessandria C , Rizzetto M , Marzano A : Lamivudine - resistant chronic hepatitis B : an observational study on adefovir in monotherapy or in combination with lamivudine .", "label": "", "metadata": {}, "score": "55.845287"}
{"text": "HBeAg seroconversion .Three studies [ 22 , 24 , 25 ] provided the data regarding HBeAg seroconversion after 48 and 96 weeks of treatment .", "label": "", "metadata": {}, "score": "55.868614"}
{"text": "The high rate of HBeAg seroconversion may be related to the rapid reduction of HBV DNA load at week 12 as mentioned above .Other studies have verified that an early reduction of HBV DNA is associated with an increased likelihood of HBeAg seroconversion [ 39 ] .", "label": "", "metadata": {}, "score": "55.950623"}
{"text": "In recent studies , TDF monotherapy produced significant suppression of HBV replication .On the other hand , there was a retrospective cohort study reporting that , with the combination of TDF and ETV , most of patients became HBV DNA undetectable after median 6 months of treatment .", "label": "", "metadata": {}, "score": "55.999138"}
{"text": "Conclusions .Patients treated with LAM plus ADV exhibited significantly greater virological , biochemical and serological responses compared with LAM alone .These data suggested that combination of LAM plus ADV would be a good option for the retreatment of CHB patients with viral relapse after cessation of LAM .", "label": "", "metadata": {}, "score": "56.024548"}
{"text": "Is currently receiving therapy with immunomodulators ( eg , corticosteroids , etc . ) , investigational agents , nephrotoxic agents , or agents susceptible of modifying renal excretion .", "label": "", "metadata": {}, "score": "56.039536"}
{"text": "Proportion of patients with resistance mutations to Adefovir , Entecavir , or Tenofovir [ Time Frame : at week 48 , 96 , 144 , and 240 of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "56.05194"}
{"text": "Brief Summary .This study will evaluate the drug telbivudine ( LdT ) for treatment of hepatitis B virus ( HBV ) in HIV infected patients .", "label": "", "metadata": {}, "score": "56.10019"}
{"text": "Proportion of patients with virologic breakthrough [ Time Frame : at 48 weeks of treatment ] [ Designated as safety issue : No ] .Current Other Outcome Measures ICMJE .", "label": "", "metadata": {}, "score": "56.327858"}
{"text": "NA : not available ; LAM : lamivudine ; ADV : adefovir ; ETV : entecavir ; RCTs : randomized controlled trials .Virologic response .", "label": "", "metadata": {}, "score": "56.375458"}
{"text": "ETV on ALT normalization 48 weeks post treatment .Virologic breakthrough .Effect of LAM + ADV vs .ETV on virologic breakthrough 48 weeks post treatment .", "label": "", "metadata": {}, "score": "56.459625"}
{"text": "Proportion of patients with resistance mutations to Adefovir , Entecavir , or Tenofovir [ Time Frame : at 48 weeks of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "56.492172"}
{"text": "10.4103/0974 - 2727.98664 View Article PubMed Central PubMed .Zhang JC : De novo combination therapy with lamivudine and adefovir dipivoxii versus entecavir monotherapy for naive chronic hepatitis B patients with high viral loads .", "label": "", "metadata": {}, "score": "56.510178"}
{"text": "PubMed View Article .Fattovich G , Rugge M , Brollo L , Pontisso P , Noventa F , Guido M , Alberti A , Realdi G : Clinical , virologic and histologic outcome following seroconversion from HBeAg to anti - HBe in chronic hepatitis type B. Hepatology 1986 , 6 : 167 - 172 .", "label": "", "metadata": {}, "score": "56.527336"}
{"text": "Patient previously received TDF for more than 1 week .Patient has a history of hepatocellular carcinoma ( HCC ) or findings suggestive of possible HCC , such as suspicious foci on imaging studies .", "label": "", "metadata": {}, "score": "56.65146"}
{"text": "Heo NY , Lim YS , Lee HC , Chung YH , Lee YS , Suh DJ : Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir .", "label": "", "metadata": {}, "score": "56.687614"}
{"text": "However , LAM mutations conferring LAM resistance have previously been shown to result in reduced susceptibility to ETV in vitro [ 33 ] and ETV exerted positive selective pressure on LAM - resistant mutants in vivo [ 34 ] .", "label": "", "metadata": {}, "score": "56.697327"}
{"text": "Currently available antiviral drugs include interferon - alpha ( INF\u03b1 ) and nucleos(t)ide analogue(NA ) polymerase inhibitors ( lamivudine , adefovir , entecavir , telbivudine and tenofovir ) .", "label": "", "metadata": {}, "score": "56.86946"}
{"text": "PubMed View Article .Chen EQ , Wang LC , Lei J , Xu L , Tang H : Meta - analysis : adefovir dipivoxil in combination with lamivudine in patients with lamivudine - resistant hepatitis B virus .", "label": "", "metadata": {}, "score": "56.99444"}
{"text": "26 , pp .2673 - 2681 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Tamori , M. Enomoto , S. Kobayashi et al . , \" Add - on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine - refractory hepatitis B virus , \" Journal of Viral Hepatitis , vol .", "label": "", "metadata": {}, "score": "57.0039"}
{"text": "PubMed View Article .Hepatology 2009 , 50 ( SUPPL.4 ) : 514A. Lee HW , Kim HJ , Choi CH , Do JH , Chang SK : Entecavir rescue therapy versus adefovir combination therapy in lamivudine - refractory patients with chronic hepatitis B. Hepatology International 2010 , 4 ( 1 ) : 132 - 133 .", "label": "", "metadata": {}, "score": "57.123314"}
{"text": "Furthermore , LAM resistance leads to the attenuation of HBV suppression and even causes hepatitis flare ups , hepatic decompensation and increased mortality rates [ 9 ] , thereby posing a serious clinical challenge .", "label": "", "metadata": {}, "score": "57.13696"}
{"text": "12 Rong - Nan Chien , Yun - Fan Liaw , Nucleos(t)ide analogues for hepatitis B virus : Strategies for long - term success , Best Practice & Research Clinical Gastroenterology , 2008 , 22 , 6 , 1081 CrossRef .", "label": "", "metadata": {}, "score": "57.213593"}
{"text": "454 - 461 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Rapti , E. Dimou , P. Mitsoula , and S. J. Hadziyannis , \" Adding - on versus switching - to adefovir therapy in lamivudine - resistant HBeAg - negative chronic hepatitis B , \" Hepatology , vol .", "label": "", "metadata": {}, "score": "57.2686"}
{"text": "[ 1 ] Hull M , Moore D , Harris M , et al .A lamivudine ( 3TC)-based backbone in conjunction with a boosted protease inhibitor ( PI ) is sufficient to achieve virologic suppression in the presence of M184V mutations .", "label": "", "metadata": {}, "score": "57.45196"}
{"text": "Ryu et al .further demonstrated that lower baseline HBV DNA levels and higher ALT levels were predictive of the virologic response [ 22 ] and Chung et al .", "label": "", "metadata": {}, "score": "57.453705"}
{"text": "10.1186/1743 - 422X-6 - 163 View Article PubMed Central PubMed .Ijaz S , Arnold C , Dervisevic S , Mechurova J , Tatman N , Tedder RS , Naoumov NV : Dynamics of lamivudine - resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy .", "label": "", "metadata": {}, "score": "57.51728"}
{"text": "Seroconversion to anti - HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point .", "label": "", "metadata": {}, "score": "57.58103"}
{"text": "There was no difference in serum creatinine concentration between the ADV and non - ADV groups at the time of enrollment .Serum phosphate concentration tended to be lower in the ADV group , although the difference was not statistically significant .", "label": "", "metadata": {}, "score": "57.581787"}
{"text": "Interventional .Study Phase .Not Provided .Study Design ICMJE .Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "57.60353"}
{"text": "Number of Participants With Grade 3 or Higher Adverse Event ( AE ) at Least One Grade Higher Than Baseline [ Time Frame : From start of randomized treatment to off randomized treatment ( up to 96 weeks ) ] .", "label": "", "metadata": {}, "score": "57.719234"}
{"text": "Wei W , Huang ZM : Effect of entecavir and lamivudine combined with adefovir in treatment of e antigen - positive chronic hepatitis B. Zhong Hua Yi Yuan Gan Ran Bing Xue Za Zhi 2012 , 22 : 4335 - 4336 .", "label": "", "metadata": {}, "score": "57.782475"}
{"text": "10.1002/jmv.21206 View Article PubMed .Rapti I , Dimou E , Mitsoula P , Hadziyannis SJ : Adding - on versus switching - to adefovir therapy in lamivudine - resistant HBeAg - negative chronic hepatitis B. Hepatology 2007 , 45 : 307 - 313 .", "label": "", "metadata": {}, "score": "57.78779"}
{"text": "Raltegravir : Raltegravir 400 mg tablet orally twice daily .Arm B : LPV / r Plus Best Available NRTIs .Participants were administered LPV / r orally twice daily , plus NRTI options provided by the study , to include the best available NRTIs .", "label": "", "metadata": {}, "score": "57.81335"}
{"text": "Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus .Gastroenterology 2004 ; 126 : 81 - 90 .", "label": "", "metadata": {}, "score": "57.84346"}
{"text": "Loss or Seroconversion Antibody to HBs ( Anti - HBs ) at Week 48 [ Time Frame : Baseline ; Week 48 ] [ Designated as safety issue : No ] . HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48 .", "label": "", "metadata": {}, "score": "57.872757"}
{"text": "In this issue of H EPATOLOGY , Rapti et al .14 report their results of a randomized controlled study of ADV therapy in 42 patients with genotype D HBV infection who had genotypic LAM resistance with virological and clinical breakthrough .", "label": "", "metadata": {}, "score": "57.881207"}
{"text": "The rtA181V / T and rtN236 T substitutions have been identified as the primary ADV - resistance mutations [ 10 ] .Substitutions at rtA181 have been found after virologic breakthrough during LAM therapy in patients who were never treated with ADV .", "label": "", "metadata": {}, "score": "57.89701"}
{"text": "Recently , it has been reported that a single amino acid change at position rt181 may induce cross - resistance to LAM and ADV [ 32 ] .", "label": "", "metadata": {}, "score": "57.957146"}
{"text": "Safety .Kim et al .[ 24 ] reported that 1 patient in the ETV monotherapy group experienced severe abdominal pain , nausea and diarrhea after 1 month of rescue treatment and treatment was therefore discontinued .", "label": "", "metadata": {}, "score": "58.125374"}
{"text": "PubMed View Article .Kao JH : Diagnosis of hepatitis B virus infection through serological and virological markers .Expert Rev Gastroenterol Hepatol 2008 , 2 : 553 - 562 .", "label": "", "metadata": {}, "score": "58.1828"}
{"text": "Hence , patients did not receive study drug except in case of patients who relapsed and reinitiated treatment .No statistical summary was performed , only patient listing was generated .", "label": "", "metadata": {}, "score": "58.229187"}
{"text": "5 Probably on the basis of this finding , it was recommended that LAM therapy be continued for 2 to 3 months to minimize the risk of ALT flare during the transition to ADV therapy .", "label": "", "metadata": {}, "score": "58.2551"}
{"text": "16 van Bommel F , Wunsche T , Mauss S , Reinke P , Bergk A , Schurmann D , et al .Comparison of adefovir and tenofovir in the treatment of lamivudine - resistant hepatitis B virus infection .", "label": "", "metadata": {}, "score": "58.26297"}
{"text": "Viral breakthrough was found in 5 patients receiving LAM alone retreatment during the 1-year observation period , and the mutations of rtM204V were found in 3 patients and rtM204I were found in 2 patients at year 1 of retreatment .", "label": "", "metadata": {}, "score": "58.288948"}
{"text": "Although there was no correlation between the length of nucleoside analogue therapy and \u0394BAP in the non - ADV group , there was a significant positive correlation between the period of ADV therapy and \u0394BAP in the ADV group ( .", "label": "", "metadata": {}, "score": "58.324356"}
{"text": "Administered orally at a total daily dosage of 300 mg for Weeks 24 - 48 .Drug : Efavirenz .Administered orally at a daily dose of 600 mg .", "label": "", "metadata": {}, "score": "58.456345"}
{"text": "PubMed View Article .Iloeje UH , Yang HI , Su J , Jen CL , You SL , Chen CJ : Predicting cirrhosis risk based on the level of circulating hepatitis B viral load .", "label": "", "metadata": {}, "score": "58.52776"}
{"text": "Lamivudine / zidovudine : Lamivudine 150 mg / zidovudine 300 mg fixed - dose combination tablet orally twice daily .Abacavir : Abacavir 300 mg tablet orally twice daily or 600 mg ( given as two 300 mg tablets ) once daily .", "label": "", "metadata": {}, "score": "58.602345"}
{"text": "Lamivudine / zidovudine : Lamivudine 150 mg / zidovudine 300 mg fixed - dose combination tablet orally twice daily .Abacavir : Abacavir 300 mg tablet orally twice daily or 600 mg ( given as two 300 mg tablets ) once daily .", "label": "", "metadata": {}, "score": "58.602345"}
{"text": "21 ] demonstrated that a lower viral load , ADV add - on therapy and IVR were independent predictors of favorable antiviral outcomes in LAM - resistant patients undergoing rescue therapy .", "label": "", "metadata": {}, "score": "58.700882"}
{"text": "Therefore , the risk of osteomalacia may increase with long - term use of ADV . .A previous report suggested that dose reduction of ADV to 10 mg every other day leads to improvement of renal function without compromising treatment efficacy [ 27 ] .", "label": "", "metadata": {}, "score": "58.72211"}
{"text": "19 Brunelle MN , Jacquard AC , Pichoud C , Durantel D , Carrouee - Durantel S , Villeneuve JP , et al .Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir .", "label": "", "metadata": {}, "score": "58.726807"}
{"text": "PubMed .Kim HJ , Park JH , Park DI , Cho YK , Sohn CI , Jeon WK , Kim BI : Rescue therapy for lamivudine - resistant chronic hepatitis B : comparison between entecavir 1.0 mg monotherapy , adefovir monotherapy and adefovir add - on lamivudine combination therapy .", "label": "", "metadata": {}, "score": "58.83396"}
{"text": "10.1097/MOT.0b013e32832b1f32 View Article PubMed .Kim HJ , Park JH , Park DI , Cho YK , Sohn CI , Jeon WK , Kim BI : Rescue therapy for lamivudine - resistant chronic hepatitis B : comparison between entecavir 1.0 mg monotherapy , adefovir monotherapy and adefovir add - on lamivudine combination therapy .", "label": "", "metadata": {}, "score": "58.86808"}
{"text": "PubMed .10.5009/gnl.2013.7.3.329 View Article PubMed .Neumann - Fraune M , Beggel B , Pfister H , Kaiser R , Verheyen J : High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates .", "label": "", "metadata": {}, "score": "58.948395"}
{"text": "ADV , adefovir ; cccDNA , covalently closed circular DNA ; ETV , entecavir ; LAM , lamivudine .Clinical studies show ADV monotherapy or ADV add - on LAM combination therapy is effective in both compensated and decompensated patients with LAM resistance .", "label": "", "metadata": {}, "score": "59.10875"}
{"text": "HBeAg seroconversion was defined as HBeAg disappearance and HBeAg antibody appearance .Viral breakthrough was defined as an increase in serum HBV DNA by 1 log 10 copies /mL above a nadir on two or more consecutive occasions at least 1 month apart .", "label": "", "metadata": {}, "score": "59.177612"}
{"text": "According to chi-and I square ( I 2 ) , heterogeneity revealed no significant differences between treatment groups .The fixed - effect approach was used to estimate of the relative risk of LAM + ADV versus ETV monotherapy .", "label": "", "metadata": {}, "score": "59.2308"}
{"text": "10.1111/j.1440 - 1746.2010.06381.x View Article PubMed .Chen EQ , Wang LC , Lei J , Xu L , Tang H : Meta - analysis : adefovir dipivoxil in combination with lamivudine in patients with lamivudine - resistant hepatitis B virus .", "label": "", "metadata": {}, "score": "59.329338"}
{"text": "PubMed View Article .Antimicrob Agents Chemother 2004 , 48 ( 9 ) : 3498 - 3507 .PubMed View Article .Villet S , Ollivet A , Pichoud C , Barraud L , Villeneuve JP , Trepo C , Zoulim F : Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient .", "label": "", "metadata": {}, "score": "59.45446"}
{"text": "10.1093/jac / dkr388 View Article PubMed .Qiu YW , Jiang XH , Huang LH , Hu TH , Ding H , Jiang YM , Dai YX , Zhou M : A study on the treatment of chronic hepatitis B with YMDD mutation .", "label": "", "metadata": {}, "score": "59.604355"}
{"text": "PubMed View Article .Virol J 2011 , 8 : 72 .PubMed View Article .Yang YF , Zhao W , Zhong YD , Xia HM , Shen L , Zhang N : Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma : a meta - analysis .", "label": "", "metadata": {}, "score": "59.680126"}
{"text": "PubMed View Article .Pawlotsky JM , Dusheiko G , Hatzakis A , Lau D , Lau G , Liang TJ , Locarnini S , Martin P , Richman DD , Zoulim F : Virologic monitoring of hepatitis B virus therapy in clinical trials and practice : recommendations for a standardized approach .", "label": "", "metadata": {}, "score": "59.778305"}
{"text": "It is therefore very important to select the right patients and the right antiviral agent(s ) and to start antiviral therapy at the right time to prevent or reduce drug resistance .", "label": "", "metadata": {}, "score": "59.837673"}
{"text": "It is now clear that rescue therapy should be instituted as soon as genotypic resistance is detected .Therefore , careful monitoring during direct antiviral therapy is mandatory for early detection and early rescue of drug resistance .", "label": "", "metadata": {}, "score": "59.85916"}
{"text": "However , the rates of HBeAg loss and seroconversion are very low with ETV [ 9 , 10 ] .Tenofovir disoproxil fumarate ( TDF ) is also been recommended as the first - line therapy agent .", "label": "", "metadata": {}, "score": "59.93522"}
{"text": "Before Beginning Anti - HIV Drugs in Patients With Both HBV and HIV .Official Title ICMJE .Multicenter , Pilot Study of Telbivudine ( LdT )", "label": "", "metadata": {}, "score": "59.95439"}
{"text": "15 Chen CH , Wang JH , Lee CM , Huang CH , Hu TH , Wang JC , et al .Virological response and incidence of adefovir resistance in lamivudine - resistant patients treated with adefovir dipivoxil .", "label": "", "metadata": {}, "score": "59.983414"}
{"text": "Taking into account of the above reasons , when viral relapse occurred after cessation of treatment , switch to agents with high genetic barrier or combination of two or more agents without cross - resistance may be good options for preventing the occurrence of drug resistance [ 9 , 20 ] .", "label": "", "metadata": {}, "score": "60.296272"}
{"text": "Conclusions .LAM plus ADV combination therapy was more effective and produced longer - lasting effects than switching to ETV monotherapy in treating CHB patients with LAM resistance .", "label": "", "metadata": {}, "score": "60.32709"}
{"text": "For comparative analyses , 19 well - matched pairs were obtained from the groups by propensity scores .At the time of enrollment , serum creatinine and phosphate concentrations were similar between the ADV and non - ADV groups ; however , urinary phosphate ( . )", "label": "", "metadata": {}, "score": "60.392395"}
{"text": "Adefovir dipivoxil therapy for lamivudine - resistant hepatitis B in pre- and post - liver transplantation patients .HEPATOLOGY 2003 ; 38 : 1419 - 1427 .", "label": "", "metadata": {}, "score": "60.44796"}
{"text": "PubMed View Article .Lok AS , Zoulim F , Locarnini S , Bartholomeusz A , Ghany MG , Pawlotsky JM , Liaw YF , Mizokami M , Kuiken C : Antiviral drug - resistant HBV : standardization of nomenclature and assays and recommendations for management .", "label": "", "metadata": {}, "score": "60.657524"}
{"text": "Cross - resistance testing of next - generation nucleoside and nucleotide analogues against lamivudine - resistant HBV .Antivir Ther 2005 ; 10 : 625 - 633 .", "label": "", "metadata": {}, "score": "60.66265"}
{"text": "PubMed .Pallier C , Rodriguez C , Brillet R , Nordmann P , Hezode C , Pawlotsky JM : Complex dynamics of hepatitis B virus resistance to adefovir .", "label": "", "metadata": {}, "score": "60.670685"}
{"text": "Compared to ADV in the treatment of nucleoside - na\u00efve HBeAg - positive patients , ETV led to a more rapid and significant decrease in HBV DNA [ 16 ] .", "label": "", "metadata": {}, "score": "60.702072"}
{"text": "Therefore a statistical analysis was not performed .One potential benefit of rapid suppression of HBV replication is to reduce the risk of drug resistance .", "label": "", "metadata": {}, "score": "60.79708"}
{"text": "This group also included 90 patients who had received 0.5 mg of ETV per day as a first - line therapy .Patients who had hypertension [ 20 ] and/or diabetes mellitus [ 21 ] were also excluded from this study owing to the risk of renal impairment .", "label": "", "metadata": {}, "score": "60.827766"}
{"text": "However , given the limited number of studies included in the analysis , caution should be exercised in extrapolation of the conclusion to all patients infected with CHB .", "label": "", "metadata": {}, "score": "60.84548"}
{"text": "[ Time Frame : Baseline ; Week 48 ] [ Designated as safety issue : No ] .Number of Participants With HBV Genotypic Changes From Baseline at Week 96 ( Resistance Surveillance )", "label": "", "metadata": {}, "score": "60.963127"}
{"text": "It has been demonstrated that the main mutations associated with LAM - resistance are rtM204I and/or rtL180 M , and these do not confer resistance to ADV [ 29 , 30 ] .", "label": "", "metadata": {}, "score": "61.097862"}
{"text": "Patient is willing and able to comply with the study drug regimen and all other study requirements .The patient is willing and able to provide written informed consent to participate in the study .", "label": "", "metadata": {}, "score": "61.126083"}
{"text": "Until recently , however , many patients commenced antiviral treatment with inferior NAs prior to the availability of TDF or ETV , such as lamivudine ( LAM ) or adefovir ( ADV ) which has a low genetic barrier to resistance .", "label": "", "metadata": {}, "score": "61.22885"}
{"text": "Your feedback is important to us , so please let us know if you have comments or ideas for improvement .Lamivudine ( LAM ) , adefovir ( ADV ) , entecavir ( ETV ) , and telbivudine are 4 approved nucleoside or nucleotide analogs for treating chronic HBV infection .", "label": "", "metadata": {}, "score": "61.431698"}
{"text": "In the present study , we found that serum BAP concentration was significantly elevated after the administration of ADV for more than 1 year .This finding was not observed after the administration of the other nucleoside analogues .", "label": "", "metadata": {}, "score": "61.447803"}
{"text": "Because we did not gain sufficient statistical information from the data presented in abstract form , these two studies were not included in our analyses [ 27 , 28 ] , and data presented in the Kim et al . study [ 24 ] ( with the exception of virologic breakthrough ) were not included in the meta - analysis .", "label": "", "metadata": {}, "score": "61.44879"}
{"text": "Antivir Ther 2006 , 11 ( 6 ) : 669 - 679 .PubMed .Ghany MG , Doo EC : Antiviral resistance and hepatitis B therapy .", "label": "", "metadata": {}, "score": "61.642807"}
{"text": "ADV has an efficacy comparable to that of LAM , but with a low drug resistance rate , and no cross resistance with other nucleoside analogues .", "label": "", "metadata": {}, "score": "61.695454"}
{"text": "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine - resistant chronic hepatitis B .Gastroenterology 2004 ; 126 : 91 - 101 .", "label": "", "metadata": {}, "score": "61.724407"}
{"text": "Telbivudine is a thymidine analogue with excellent HBV inhibitory activity but no anti - HIV activity .The primary objective of this study is to evaluate the safety and anti - HBV activity of telbivudine alone and in combination with a lamivudine - based highly active antiretroviral therapy ( HAART ) regimen in patients coinfected with HBV and HIV .", "label": "", "metadata": {}, "score": "61.779335"}
{"text": "Chronic Hepatitis B .Intervention ICMJE .Drug : TDF .Tenofovir disoproxil fumarate ( TDF ) 300 mg tablet administered orally once daily .Other Name : Viread \u00ae .", "label": "", "metadata": {}, "score": "61.841873"}
{"text": "5 , pp .328 - 334 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. A. Fux , A. Rauch , M. Simcock et al . , \" Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study , \" Antiviral Therapy , vol .", "label": "", "metadata": {}, "score": "61.906013"}
{"text": "17 Sherman M , Yurdaydin C , Sollano J , Silva M , Liaw YF , Cianciara J , et al .Entecavir for treatment of lamivudine - refractory , HBeAg - positive chronic hepatitis B .", "label": "", "metadata": {}, "score": "61.975544"}
{"text": "PubMed View Article .Villet S , Pichoud C , Billioud G , Barraud L , Durantel S , Trepo C , Zoulim F : Impact of hepatitis B virus rtA181V / T mutants on hepatitis B treatment failure .", "label": "", "metadata": {}, "score": "62.182457"}
{"text": "Over the past two decades , treatment of CHB has greatly improved with the availability of nucleos(t)ide analogs .The sustained suppression of serum HBV DNA to very low or undetectable levels has been associated with the prevention liver disease progression and inhibition of the development of long - term complications [ 6 , 7 , 29 ] .", "label": "", "metadata": {}, "score": "62.237392"}
{"text": "10.1002/jmv.23530 View Article PubMed .Liver Int 2013 , 33 : 244 - 254 .10.1111/liv.12036 View Article PubMed .Sinn DH , Lee H , Gwak GY , Choi MS , Koh KC , Paik SW , Yoo BC , Lee JH : Viroligic response to adefovir monotherapy and the risk of adefovir resistance .", "label": "", "metadata": {}, "score": "62.755"}
{"text": "Percentage of Participants With HBsAgLoss and/or Seroconversion to Anti - HBs at Week 96 [ Time Frame : Baseline ; Week 96 ] [ Designated as safety issue : No ] . HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96 .", "label": "", "metadata": {}, "score": "62.905373"}
{"text": "Of the studies identified , three were RCTs [ 22 , 23 , 25 ] ; one study [ 23 ] was published in Chinese and two published in English .", "label": "", "metadata": {}, "score": "63.092327"}
{"text": "However , in the present study , patients did not present with symptoms of Fanconi syndrome ; this finding may indicate that ADV plus LAM combination therapy is fairly safe for almost all patients if appropriate monitoring is provided for adverse effects of ADV . .", "label": "", "metadata": {}, "score": "63.096817"}
{"text": "65 - 85 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. B. D'Agostino Jr. , \" Propensity score methods for bias reduction in the comparison of a treatment to a non - randomized control group , \" Statistics in Medicine , vol .", "label": "", "metadata": {}, "score": "63.266052"}
{"text": "1 The study by Rapti et al .14 proved the concept that combination therapy prevents or delays drug resistance and underscores the need to evaluate de novo combination of antiviral agents to maintain long - term and complete viral suppression .", "label": "", "metadata": {}, "score": "63.28144"}
{"text": "Hepatology 2007 , 46 : 690 - 698 .10.1002/hep.21758 View Article PubMed .Wu B , Shen J , Cheng H : Cost - effectiveness analysis of different rescue therapies in patients with lamivudine - resistant chronic hepatitis B in China .", "label": "", "metadata": {}, "score": "63.28706"}
{"text": "Analysis of Serological and DNA Markers for HBV . HBsAg in patients ' sera was tested by enzyme immunoassay using commercially available kits ( Dainabott , Tokyo , Japan ) .", "label": "", "metadata": {}, "score": "63.2976"}
{"text": "Changes in Serum Creatinine , Phosphate , and ALP Isoenzymes before and after Administration of Nucleos(t)ide Analogues .There were no significant changes in serum creatinine or serum phosphate concentration with the administration of ADV or the other nucleoside analogues ( LAM or ETV ) ( Figure 3 ) .", "label": "", "metadata": {}, "score": "63.32046"}
{"text": "Zhang Q , Cheng ML , Liu Q , Mu M , Zhang YY , Liu BY : Efficacy of entecavir in nucleoside - naive patients with hepatitis B e antigen - positive chronic hepatitis B. World Chin J Digestol 2009 , 17 : 2846 - 2849 .", "label": "", "metadata": {}, "score": "63.33639"}
{"text": "Thus , the prudent selection of appropriate agents for the initial treatment of CHB patients to achieve an efficacy , while simultaneously avoiding the emergence of resistance , is a vital clinical concern .", "label": "", "metadata": {}, "score": "63.344055"}
{"text": "In clinical practice , a variety of retreatment strategies have been applied , including back to their original drug , switch to another drugs , or two or more drugs in combination .", "label": "", "metadata": {}, "score": "63.35986"}
{"text": "Therefore , it was difficult to detect potential renal dysfunction on the basis of elevation in serum creatinine concentration alone .According to a recent report , the maximal reabsorption of phosphate in the renal tubules and serum phosphate concentration were low in several patients receiving ADV ; however , after changing therapy to ETV , serum phosphate concentration improved [ 25 ] .", "label": "", "metadata": {}, "score": "63.38081"}
{"text": "Hepatol Int 2012 , 6 : 531 - 561 .10.1007/s12072 - 012 - 9365 - 4 View Article .Shepherd J , Gospodarevskaya E , Frampton G , Cooper K : Entecavir for the treatment of chronic hepatitis B infection .", "label": "", "metadata": {}, "score": "63.420105"}
{"text": "HBeAg loss or seroconversion may reduce the risk of developing HCC or progressive liver diseases [ 41 ] in HBeAg - positive CHB patients .This suggests that superiority of combination of LAM and ADV over ETV alone in term of HBeAg seroconversion may provide potential benefits in patients with HBeAg - positive CHB .", "label": "", "metadata": {}, "score": "63.44668"}
{"text": "PubMed .View Article PubMed .Yao GB , Zhu M , Cui ZY , Wang BE , Yao JL , Zeng MD : A 7-year study of lamivudine therapy for hepatitis B virus e antigen - positive chronic hepatitis B patients in China .", "label": "", "metadata": {}, "score": "63.4594"}
{"text": "However , nearly 40 % of the relapses or virological breakthroughs were not related to antiviral drug resistance .For example , due to the poverty , many CHB patients in Asia can not afford their long - term medication , and they always terminated their treatment just when reaching virological response irrespective of the occurrence of HBeAg seroconversion .", "label": "", "metadata": {}, "score": "63.689125"}
{"text": "All patients had to have excellent compliance in taking the antiviral agents .Our search was limited to human studies and the following exclusion criteria were used : ( 1 ) non - comparative study ; retrospective study , observational study .", "label": "", "metadata": {}, "score": "63.693092"}
{"text": "Proportion of patients with normal ALT [ Time Frame : at week 48 , 96 , 144 , and 240 of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "63.699635"}
{"text": "Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .Experimental : Tenofovir plus Entecavir combination .", "label": "", "metadata": {}, "score": "63.773678"}
{"text": "HCC : .Hepatocellular Carcinoma .HIV : .Human immunodeficiency virus .RCTs : .Randomized controlled trials .NAS : .Nucleos(t)ide analogues .", "label": "", "metadata": {}, "score": "63.82457"}
{"text": "3 Geoffrey Dusheiko , Treatment of HBeAg positive chronic hepatitis B : interferon or nucleoside analogues , Liver International , 2013 , 33 , 137 Wiley Online Library .", "label": "", "metadata": {}, "score": "63.86773"}
{"text": "Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Tenofovir Plus Entecavir vs. Tenofovir in Adefovir - Resistant Chronic Hepatitis B .", "label": "", "metadata": {}, "score": "63.87052"}
{"text": "6 , pp .923 - 931 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. J. Hadziyannis , N. C. Tassopoulos , E. J. Heathcote et al . , \" Adefovir dipivoxil for the treatment of hepatitis B e antigen - negative chronic hepatitis B , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "63.983227"}
{"text": "Therefore , treatment must often be administered long - term .Unfortunately , prolonged therapy is associated with the development of drug resistance [ 2 ] .", "label": "", "metadata": {}, "score": "64.01958"}
{"text": "Currently , some studies have carried out direct comparisons between the antiviral efficacies of the respective rescue strategies .The aim of this analysis was arrive at an evidence - based conclusion based on available data regarding the efficacy of both rescue strategies .", "label": "", "metadata": {}, "score": "64.02466"}
{"text": "10.1002/hep.22524 View Article PubMed .Patterson SJ , Angus PW : Post - liver transplant hepatitis B prophylaxis : the role of oral nucleos(t)ide analogues .", "label": "", "metadata": {}, "score": "64.296"}
{"text": "Study quality .One study was an RCT and stated the method of randomization , withdrawal and allocation concealment , but did not describe the blinding .", "label": "", "metadata": {}, "score": "64.49194"}
{"text": "Dienstag JL : Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009 , 49 : S112-S121 .10.1002/hep.22920 View Article PubMed .", "label": "", "metadata": {}, "score": "64.69029"}
{"text": "Current Secondary Outcome Measures ICMJE ( submitted : June 24 , 2015 ) .Changes in serum HBV DNA levels [ Time Frame : at week 48 , 96 , 144 , and 240 of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "65.0441"}
{"text": "Compensated liver disease ( Child - Pugh class A ) . HBsAg positive at least 6 months or more .HBeAg positive or negative .Confirmation of ADV resistance mutation at any time before screening ( rtA181V or rtA181 T or rtN236 T ) .", "label": "", "metadata": {}, "score": "65.16533"}
{"text": "Figure 4 : Transition of serum ALP2 and BAP concentrations from before medical treatment to at the time of at least 1 year or more after starting nucleos(t)ide analogue therapy in ADV group and non - ADV group .", "label": "", "metadata": {}, "score": "65.19084"}
{"text": "10.3748/wjg.v17.i30.3526 View Article PubMed Central PubMed .Villet S , Pichoud C , Billioud G , Barraud L , Durantel S , Trepo C , Zoulim F : Impact of hepatitis B virus rtA181V / T mutants on hepatitis B treatment failure .", "label": "", "metadata": {}, "score": "65.25864"}
{"text": "Song BC , Suh DJ , Lee HC , Chung YH , Lee YS : Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea .", "label": "", "metadata": {}, "score": "65.34892"}
{"text": "Quality assessment of the respective studies analyzed demonstrated that the RCTs had Jadad scores that ranged between1 - 5 .Two full manuscripts [ 22 , 23 ] and one abstract [ 25 ] were RCTs and described withdrawn , but they did not describe the method of randomization in detail ; these three studies received Jadad scores of 2 .", "label": "", "metadata": {}, "score": "65.688614"}
{"text": "After modification of the ADV dose , serum creatinine levels declined .Another study reported that renal function was normal during the time of rescue treatment [ 23 ] .", "label": "", "metadata": {}, "score": "65.70383"}
{"text": "8 Cesare Sarrecchia , Antonio Volpi , Pasquale Sordillo , Massimo Andreoni , Multidrug resistance after lamivudine therapy for chronic hepatitis B , International Journal of Infectious Diseases , 2009 , 13 , 3 , e133 CrossRef .", "label": "", "metadata": {}, "score": "65.83667"}
{"text": "Lim SG , Cheng Y , Guindon S , Seet BL , Lee LY , Hu P , Wasser S , Peter FJ , Tan T , Goode M , Rodrigo AG : Viral quasi - species evolution during hepatitis Be antigen seroconversion .", "label": "", "metadata": {}, "score": "65.837036"}
{"text": "PubMed View Article .Lok AS , McMahon BJ : Chronic hepatitis B : update 2009 .Hepatology 2009 , 50 ( 3 ) : 661 - 662 .", "label": "", "metadata": {}, "score": "65.907585"}
{"text": "At present , switching to ETV is not recommended for rescue therapy for LAM - resistant chronic hepatitis B ( CHB ) .The aim of this report was to determine whether add - on ADV was a superior rescue strategy in the treatment of CHB patients with LAM resistance .", "label": "", "metadata": {}, "score": "65.93172"}
{"text": "When several publications pertaining to a single study were identified , the most recent and complete publication was used to prevent duplication of data .Quality assessment .", "label": "", "metadata": {}, "score": "65.95393"}
{"text": "Together , these observations indicate that there is a controversy about the efficacy of TDF monotherapy in patients with genotypic resistance to ADV . .Thus , in this clinical trial , the investigators will clarify whether tenofovir monotherapy is effective in inducing complete virologic response compared with tenofovir plus entecavir in CHB patients with genotypic resistance to ADV and partial virologic response to ongoing treatment .", "label": "", "metadata": {}, "score": "65.96109"}
{"text": "In this meta - analysis , either combination group or ETV alone was well tolerated .Only one patient presented with an elevated BUN in the combination group .", "label": "", "metadata": {}, "score": "66.17878"}
{"text": "Studies have demonstrated that the risk of liver disease progression in patients with CHB is associated with elevated HBV DNA levels [ 3 , 4 ] .", "label": "", "metadata": {}, "score": "66.234695"}
{"text": "Ranked Assessment of Necroinflammation and Fibrosis at Week 48 [ Time Frame : Baseline ; Week 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.36867"}
{"text": "The authors declare that there are no conflicts of interest to declare . E. B. Keeffe , D. T. Dieterich , S.-H. B. Han et al . , \" A treatment algorithm for the management of chronic hepatitis B virus infection in the united states : 2008 update , \" Clinical Gastroenterology and Hepatology , vol .", "label": "", "metadata": {}, "score": "66.566795"}
{"text": "More high - quality , well - designed , randomized controlled , multi - center trails that are adequately powered will clearly be needed to guide evolving standards of care for treating CHB patients with LAM resistance .", "label": "", "metadata": {}, "score": "66.65228"}
{"text": "123 - 129 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Ure\u00f1a , M. Hruby , A. Ferreira , K. S. Ang , and M.-C. De Vernejoul , \" Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients , \" Journal of the American Society of Nephrology , vol .", "label": "", "metadata": {}, "score": "66.717964"}
{"text": "Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score .", "label": "", "metadata": {}, "score": "66.72031"}
{"text": "Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score .", "label": "", "metadata": {}, "score": "66.72031"}
{"text": "17 Considering the selection advantage of LAM - resistant strains , it is conceivable that switching to ETV monotherapy is more appropriate than ETV add - on LAM combination therapy for LAM - resistant patients .", "label": "", "metadata": {}, "score": "66.927185"}
{"text": "710 - 719 , 2013 .View at Google Scholar .M. A. Jhaveri , H. W. Mawad , A. C. Thornton , N. W. Mullen , and R. N. Greenberg , \" Tenofovir - associated severe bone pain : i can not walk ! , \" Journal of the International Association of Physicians in AIDS Care , vol .", "label": "", "metadata": {}, "score": "67.0347"}
{"text": "However , the data for tenofovir are still limited , and the drug has not been approved for hepatitis B patients .Because cost is a concern and a large number of patients are currently being and will be treated with LAM , the least expensive drug , LAM resistance remains a serious clinical challenge for the foreseeable future .", "label": "", "metadata": {}, "score": "67.04406"}
{"text": "Chronic hepatitis B : update of recommendations .HEPATOLOGY 2004 ; 39 : 857 - 861 .8 Kim KM , Choi WB , Lim YS , Lee HC , Chung YH , Lee YS , et al .", "label": "", "metadata": {}, "score": "67.08597"}
{"text": "We searched Medline / PubMed , EMBASE , Web of Knowledge , and the Cochrane Library .Relative risks ( RRs ) of virologic response , virologic breakthrough , normalization of serum alanine aminotransferase ( ALT ) levels and HBeAg seroconversion rates were studied .", "label": "", "metadata": {}, "score": "67.519104"}
{"text": "Furthermore , 2 adult patients with acquired immunodeficiency syndrome presented with severe bone pain associated with TDF [ 28 ] , which is also used for the treatment of chronic HBV infection - related liver disease in Japan and is associated with an increase in serum ALP [ 29 ] .", "label": "", "metadata": {}, "score": "67.533554"}
{"text": "PubMed View Article .Carey I , Harrison PM : Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009 , 18 : 1655 - 1666 .", "label": "", "metadata": {}, "score": "67.54329"}
{"text": "Second , studies included in this systematic review were few and had small sample sizes .Third , studies published in abstract form ( and some additional studies ) did not report data that could be included in the meta - analysis ; therefore , we could not carry out a deep analysis .", "label": "", "metadata": {}, "score": "67.64561"}
{"text": "Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "67.77609"}
{"text": "When heterogeneity was confirmed , the random - effect method was used .Additionally , sensitivity analysis was carried out if low quality studies were included .", "label": "", "metadata": {}, "score": "67.79979"}
{"text": "We used the relative risk ( RR ) of the main dichotomous outcomes as the measure of efficacy .The 95 % confidence interval ( CI ) for the combined RR was also provided .", "label": "", "metadata": {}, "score": "68.00526"}
{"text": "PubMed View Article .PubMed View Article .PubMed View Article .Qiu YW , Jiang XH , Huang LH , Hu TH , Ding H , Jiang YM , Dai YX , Zhou M : [ A study on the treatment of chronic hepatitis B with YMDD mutation].", "label": "", "metadata": {}, "score": "68.07359"}
{"text": "References .Lai CL , Ratziu V , Yuen MF , Poynard T : Viral hepatitis B. Lancet 2003 , 362 : 2089 - 2094 .", "label": "", "metadata": {}, "score": "68.24385"}
{"text": "Adefovir dipivoxil ( ADV ) 10 mg tablet administered orally once daily .Other Name : Hepsera \u00ae .Drug : TDF placebo .Placebo to match TDF administered orally once daily .", "label": "", "metadata": {}, "score": "68.355484"}
{"text": "In patients with LAM resistance , tenofovir ( TDF , not yet approved for use in Japan ) or ADV therapy is advised [ 10 ] .", "label": "", "metadata": {}, "score": "68.568695"}
{"text": "Clin Pharm 2010 , 2 : 17 - 21 .Hepatology 2009 , 49 : 1503 - 1514 .10.1002/hep.22841 View Article PubMed .", "label": "", "metadata": {}, "score": "68.637886"}
{"text": "Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study .Patient has concomitant other chronic viral infection ( HCV or HIV ) .", "label": "", "metadata": {}, "score": "68.686295"}
{"text": "10.1097/00042737 - 200112000 - 00016 View Article .Yu MM , Gu XJ , Xia Y , Wang GJ , Kan NY , Wu KH : Relationship between the expression of HBV DNA , HBV cccDNA in human ovary tissues and the HBV intrauterine infection .", "label": "", "metadata": {}, "score": "68.75069"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Department of Infectious Diseases , Institute for Viral Hepatitis , Key Laboratory of Molecular Biology for Infectious Diseases , Ministry of Education , The Second Affiliated Hospital of Chongqing Medical University .", "label": "", "metadata": {}, "score": "68.96968"}
{"text": "Computer searches were supplemented with manual search .Two authors ( Fen Liu and Xiwei Wang ) independently screened all citations and abstracts to identify potentially eligible studies .", "label": "", "metadata": {}, "score": "69.16064"}
{"text": "10.1111/j.1751 - 2980.2009.00375.x View Article PubMed .Zoulim F , Locarnini S : Management of treatment failure in chronic hepatitis B. J Hepatol 2012 , 56 : S112-S122 .", "label": "", "metadata": {}, "score": "69.27812"}
{"text": "Improvement is defined as a 2-point or greater reduction in CTP score , and stabilization is defined as a less than 2-point change in CTP score , compared to the patient 's baseline value .", "label": "", "metadata": {}, "score": "69.30846"}
{"text": "Improvement is defined as a 2-point or greater reduction in CTP score , and stabilization is defined as a less than 2-point change in CTP score , compared to the patient 's baseline value .", "label": "", "metadata": {}, "score": "69.30846"}
{"text": "Percentage of Participants With Histological Response at Week 48 [ Time Frame : Baseline ; Week 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.37026"}
{"text": "Currently , there is no consensus on the efficacy and resistance of de novo combination therapy versus monotherapy for treatment naive patients of chronic hepatitis B ( CHB ) .", "label": "", "metadata": {}, "score": "69.40119"}
{"text": "Van Damme P , Zanetti AR , Shouval D , Van Herck K : Strategies for global prevention of hepatitis B virus infection .Adv Exp Med Biol 2010 , 659 : 175 - 188 .", "label": "", "metadata": {}, "score": "69.516975"}
{"text": "ETV , known for its potent antiviral effects , has a high genetic barrier to resistance , as more than three sites are required for drug resistance to develop [ 7 ] .", "label": "", "metadata": {}, "score": "69.64061"}
{"text": "One was found with the full - text which had been included in the study , and the other was excluded because of a lack of sufficient statistical data .", "label": "", "metadata": {}, "score": "69.67289"}
{"text": "We obtained full articles and abstracts for all potentially relevant trials and the reference lists from retrieved documents were also searched .To maximize data requisition , we contacted authors whose articles contained insufficient information .", "label": "", "metadata": {}, "score": "70.15662"}
{"text": "Materials and Methods .Patients .This study complies with the standards of the 1975 Declaration of Helsinki and current ethical guidelines ; written informed consent was obtained from each patient .", "label": "", "metadata": {}, "score": "70.20038"}
{"text": "The limitations of this review include the fact that some studies were not RCTs .Publication bias was also possible .Compared to positive studies , negative studies may be less likely to be published and more likely to take longer to be published .", "label": "", "metadata": {}, "score": "70.37195"}
{"text": "Willing and able to provide written informed consent .Had a liver biopsy performed within 6 months of baseline and has readable biopsy slides or agrees to have a biopsy performed prior to baseline .", "label": "", "metadata": {}, "score": "70.431046"}
{"text": "\u0394BAP ; ( serum BAP concentration at the time of at least 1 year or more after starting nucleos(t)ide analogue therapy)-(serum BAP concentration before treatment ) .", "label": "", "metadata": {}, "score": "70.52975"}
{"text": "Outcomes were analyzed on an intent - to - treat basis .Meta - analysis was performed using fixed effect or random - effect methods , depending on the absence or presence of significant heterogeneity .", "label": "", "metadata": {}, "score": "70.552925"}
{"text": "Brief Title ICMJE .A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg - Negative Chronic Hepatitis B .Official Title ICMJE .", "label": "", "metadata": {}, "score": "70.8295"}
{"text": "Thus , a random - effects model was used .There were three studies [ 22 , 24 , 25 ] that reported the ALT normalization rates at 96 weeks .", "label": "", "metadata": {}, "score": "70.87673"}
{"text": "NA : not available ; NS : not significant ; iLAM : lamivudine ; ADV : adefovir ; ETV : entecavir ; SD : Standard Deviation ; RCTs : randomized controlled trials .", "label": "", "metadata": {}, "score": "71.01782"}
{"text": "Recruited at international AIDS Clinical Trials Group Units .Recruitment occurred between March 13 , 2012 ( date first participant was randomized ) and October 2 , 2013 ( date last participant was randomized ) .", "label": "", "metadata": {}, "score": "71.244446"}
{"text": "14 Ilan S. Weisberg , Robert S. Brown , Samuel H. Sigal , Hepatitis B and End - Stage Liver Disease , Clinics in Liver Disease , 2007 , 11 , 4 , 893 CrossRef .", "label": "", "metadata": {}, "score": "71.2672"}
{"text": "2265 - 2281 , 1998 .View at Google Scholar .M. M. Joffe and P. R. Rosenbaum , \" Invited commentary : propensity scores , \" American Journal of Epidemiology , vol .", "label": "", "metadata": {}, "score": "71.34041"}
{"text": "Outcomes were analyzed on an intent - to - treat basis .For each eligible study , dichotomous data were presented as relative risk ( RR ) with 95 % confidence intervals ( CI ) .", "label": "", "metadata": {}, "score": "71.37936"}
{"text": "However , this finding was not observed after administration of the other nucleoside analogues .Therefore , osteomalacia caused by renal tubular impairment may be a unique side effect of ADV , especially after long - term use of ADV . .", "label": "", "metadata": {}, "score": "71.55101"}
{"text": "Background .Antiviral therapy is used in CHB to minimize the liver damage and progression of disease [ 3 ] , but total eradication of the HBV is seldom achieved by current treatment , especially for patients who infected HBV in early childhood .", "label": "", "metadata": {}, "score": "71.81151"}
{"text": "LAM was the first one to be approved by the United States Food and Drug Administration and has a well - established safety and efficacy profile .", "label": "", "metadata": {}, "score": "71.839645"}
{"text": "However , a major shortcoming of LAM - based therapies is the development of drug resistant strains that develop with increasing frequency with treatment duration .", "label": "", "metadata": {}, "score": "71.89984"}
{"text": "Pawlotsky JM : EASL Clinical Practice Guidelines .J Hepatol 2009 , 50 ( 2 ) : 243 .PubMed View Article .Jadad AR , Moore RA , Carroll D , Jenkinson C , Reynolds DJ , Gavaghan DJ , McQuay HJ : Assessing the quality of reports of randomized clinical trials : is blinding necessary ?", "label": "", "metadata": {}, "score": "71.96927"}
{"text": "11 , pp .1983 - 1992 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Kuzuya , S. Nakagawa , J. Satoh et al . , \" Report of the committee on the classification and diagnostic criteria of diabetes mellitus , \" Diabetes Research and Clinical Practice , vol .", "label": "", "metadata": {}, "score": "72.01543"}
{"text": "Discussion .Currently , all NAS approved to treat CHB have inhibitory effects on the HBV polymerase / reverse transcriptase , which has poor proofreading and editing ability , resulting in error - prone replication [ 26 ] .", "label": "", "metadata": {}, "score": "72.34475"}
{"text": "Of the five studies , two were published in English , and the others were published in Chinese .All studied populations had comparable baseline characteristics between the two groups .", "label": "", "metadata": {}, "score": "72.37038"}
{"text": "Once viral breakthrough or drug resistance occurs , rescue therapy was been initiated .But , rescue therapy can promote the development of multidrug mutations [ 19 ] .", "label": "", "metadata": {}, "score": "72.41655"}
{"text": "WF , WXW , HHD and ZDZ participated in the analysis and interpretation of data .All authors read and approved the final manuscript .Authors ' Affiliations .", "label": "", "metadata": {}, "score": "72.575455"}
{"text": "Emtricitabine / tenofovir disoproxil fumarate : Emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg fixed - dose combination tablet orally once daily .Abacavir / lamivudine / zidovudine : Abacavir 300 mg / lamivudine 150 mg / zidovudine 300 mg fixed - dose combination tablet orally twice daily .", "label": "", "metadata": {}, "score": "72.58496"}
{"text": "Emtricitabine / tenofovir disoproxil fumarate : Emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg fixed - dose combination tablet orally once daily .Abacavir / lamivudine / zidovudine : Abacavir 300 mg / lamivudine 150 mg / zidovudine 300 mg fixed - dose combination tablet orally twice daily .", "label": "", "metadata": {}, "score": "72.58496"}
{"text": "Two authors ( Yun - Jian Sheng and Jun - Ying Liu ) independently extracted the data using a pre - designed data extraction form .", "label": "", "metadata": {}, "score": "72.70896"}
{"text": "Cao GW : Clinical relevance and public health significance of hepatitis B virus genomic variations .World J Gastroenterol 2009 , 15 ( 46 ) : 5761 - 5769 .", "label": "", "metadata": {}, "score": "72.716354"}
{"text": "For RCT : methodological quality was assessed using the Jadad quality scale .We examined the allocation sequence generation , allocation concealment , application of blinding method , and dropouts and withdrawals .", "label": "", "metadata": {}, "score": "72.757"}
{"text": "The search process was designed to find all studies involving terms : \" chronic Hepatitis B \" , \" entecavir \" , \" adefovir dipivoxil \" , \" lamivudine \" ( and multiple synonyms for each term ) .", "label": "", "metadata": {}, "score": "72.786575"}
{"text": "Lok AS , McMahon BJ : Chronic hepatitis B : update 2009 .Hepatology 2009 , 50 : 661 - 662 .PubMed View Article .", "label": "", "metadata": {}, "score": "72.81532"}
{"text": "Pregnant women , women who are breast feeding , or women who believe they may wish to become pregnant during the course of the study .", "label": "", "metadata": {}, "score": "72.976105"}
{"text": "This study was approved by Chengdu Military General Hospital 's institutional review board and was conducted in accordance with the 1975 Declaration of Helsinki .Serum assay methodology .", "label": "", "metadata": {}, "score": "73.49442"}
{"text": "Nucleos(t)ide analogue therapies are very useful for the treatment of chronic HBV infection - related liver disease , have few adverse effects with subjective symptoms , and are often used in long - term treatment .", "label": "", "metadata": {}, "score": "73.70946"}
{"text": "( 3 ) Patients co - infected with hepatitis A , C , D and E virus , who had decompensated liver disease , hepatocellular carcinoma ( HCC ) .", "label": "", "metadata": {}, "score": "73.85898"}
{"text": "Placebo to match ADV administered orally once daily .Drug : FTC / TDF .Emtricitabine ( FTC ) 200 mg / TDF 300 mg fixed - dose combination ( FDC ) tablet administered orally once daily .", "label": "", "metadata": {}, "score": "73.86952"}
{"text": "Condition : .Drug : Lopinavir / ritonavir Drug : Raltegravir Drug : Emtricitabine / tenofovir disoproxil fumarate Drug : Abacavir / lamivudine / zidovudine Drug : Abacavir / lamivudine Drug : Lamivudine / zidovudine Drug : Abacavir Drug : Zidovudine Drug : Lamivudine .", "label": "", "metadata": {}, "score": "73.96512"}
{"text": "History of ascites , variceal hemorrhage , or hepatic encephalopathy .Gender .Both .Ages .20 Years to 75 Years .Accepts Healthy Volunteers .", "label": "", "metadata": {}, "score": "74.23308"}
{"text": "J Hepatol 2006 ; 44 : 283 - 290 .11 Yeon JE , Yoo W , Hong SP , Chang YJ , Yu SK , Kim JH , et al .", "label": "", "metadata": {}, "score": "74.4193"}
{"text": "Wang et al .[21 ] reported that in the combination group , one patient 's the blood urea nitrogen ( BUN ) increased to 7.87 mol / L at week 24 without a concomitant increase in serum creatinine ( Scr ) .", "label": "", "metadata": {}, "score": "74.42613"}
{"text": "Ganem D , Prince AM : Hepatitis B virus infection -- natural history and clinical consequences .N Engl J Med 2004 , 350 ( 11 ) : 1118 - 1129 .", "label": "", "metadata": {}, "score": "74.4591"}
{"text": "PubMed View Article .EASL Clinical Practice Guidelines : management of chronic hepatitis B J Hepatol 2009 , 50 : 227 - 242 .Guideline on prevention and treatment of chronic hepatitis B in China ( 2005 )", "label": "", "metadata": {}, "score": "74.48045"}
{"text": "Chen CJ , Yang HI , Su J , Jen CL , You SL , Lu SN , Huang GT , Iloeje UH : Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level .", "label": "", "metadata": {}, "score": "74.55815"}
{"text": "The safety was assessed by compiling adverse events including renal dysfunction , decompensation of cirrhosis and HCC .Data extraction .Two investigators independently screened abstracts , selected the studies and performed the data extraction .", "label": "", "metadata": {}, "score": "74.595024"}
{"text": "PubMed View Article .PubMed View Article .Lok AS , McMahon BJ : Chronic hepatitis B. Hepatology 2007 , 45 ( 2 ) : 507 - 539 .", "label": "", "metadata": {}, "score": "74.96116"}
{"text": "Lavanchy D : Hepatitis B virus epidemiology , disease burden , treatment , and current and emerging prevention and control measures .J Viral Hepat 2004 , 11 : 97 - 107 .", "label": "", "metadata": {}, "score": "75.943375"}
{"text": "Abstract H-916 .Abstract .Background .Chronic hepatitis B virus ( HBV ) infection represents a serious global health problem and resistance to lamivudine ( LAM ) has become a serious clinical challenge .", "label": "", "metadata": {}, "score": "76.30803"}
{"text": "Original Secondary Outcome Measures ICMJE .Not Provided .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .", "label": "", "metadata": {}, "score": "76.4581"}
{"text": "Chronic Hepatitis B Lamivudine Adefovir Entecavir Resistance Combination therapy .Background .Chronic hepatitis B virus infection ( HBV ) poses a serious global health problem based on the approximately 350 million individuals suffering from chronic hepatitis B ( CHB ) infection worldwide [ 1 ] .", "label": "", "metadata": {}, "score": "76.90979"}
{"text": "Data analysis was carried out with the use of Review Manager Software 5.0 ( Cochrane Collaboration , Oxford , United Kingdom ) .Results .Search results and characteristics .", "label": "", "metadata": {}, "score": "77.05612"}
{"text": "A decrease of 1 point or more indicated improvement , and an increase of 1 point or more indicated worsening .Percentage of Participants With ALT Normalization at Week 48 [ Time Frame : Baseline ; Week 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "77.07555"}
{"text": "PubMed View Article .Copyright .\u00a9 Wang et al ; licensee BioMed Central Ltd. 2011 .Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "77.138336"}
{"text": "Clin Infect Dis 2004 , 38 : 490 - 495 .PubMed View Article .Zoulim F : Hepatitis B virus resistance to antiviral drugs : where are we going ?", "label": "", "metadata": {}, "score": "77.27219"}
{"text": "Gut 2006 ; 55 : 1488 - 1495 .12 Lee YS , Suh DJ , Lim YS , Jung SW , Kim KM , Lee HC , et al .", "label": "", "metadata": {}, "score": "77.645775"}
{"text": "HEPATOLOGY 2006 ; 43 : 1385 - 1391 .13 Lampertico P , Vigano M , Manenti E , Iavarone M , Lunghi G , Colombo M .", "label": "", "metadata": {}, "score": "77.783615"}
{"text": "Copyright .\u00a9 Sheng et al ; licensee BioMed Central Ltd. 2011 .Abstract .Aim .Currently , there is no consensus on the retreatment recommendation of chronic hepatitis B ( CHB ) patients with viral rebound after cessation of treatment .", "label": "", "metadata": {}, "score": "78.29591"}
{"text": "Includes whether analysis was per protocol , intention to treat , or another method .Also provides relevant details such as imputation technique , as appropriate .", "label": "", "metadata": {}, "score": "78.44389"}
{"text": "These findings may be attributed to the increase in urinary phosphate that occurs before a decrease in serum phosphate .Therefore , monitoring for an increase in urinary phosphate may be critical for earlier detection of osteomalacia caused by renal tubular impairment .", "label": "", "metadata": {}, "score": "78.63977"}
{"text": "Examination of Bone Turnover Markers .\u0394BAP , a sensitive marker reflecting the changes in bone metabolism , was calculated as follows : serum BAP concentration at the time of enrollment minus serum BAP concentration before administration of nucleos(t)ide analogues .", "label": "", "metadata": {}, "score": "78.64577"}
{"text": "Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Elevation in Serum Concentration of Bone - Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection .", "label": "", "metadata": {}, "score": "79.116325"}
{"text": "A P - value of less than 0.05 ( two - tailed ) was considered to indicate a significant difference .All statistical analyses were performed using the SPSS software package version 13.0 ( SPSS Inc. , Chicago , IL ) .", "label": "", "metadata": {}, "score": "79.42531"}
{"text": "Authors ' contributions .RH and HP conceived the study , provided funding supporting and revised the manuscript critically for important intellectual content .SYJ made substantial contributions to its design , acquisition , analysis and interpretation of data .", "label": "", "metadata": {}, "score": "79.55414"}
{"text": "Introduction .Chronic hepatitis B virus ( HBV ) infection causing chronic hepatitis , cirrhosis , and hepatocellular carcinoma affects more than 350 million people worldwide [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "79.59666"}
{"text": "Literature search .Medline / PubMed , EMBASE , Web of Knowledge and the Cochrane Library were searched for relevant articles through March 24 th , 2011 without language limitation .", "label": "", "metadata": {}, "score": "79.852776"}
{"text": "Patient is currently abusing alcohol ( more than 40 g / day ) or illicit drugs , or has a history of alcohol abuse or illicit substance abuse within the preceding two years .", "label": "", "metadata": {}, "score": "80.19539"}
{"text": "XH , YZ , JPQ participated in the design , analysis and interpretation of data .All authors read and approved the final manuscript .Authors ' Affiliations .", "label": "", "metadata": {}, "score": "80.94116"}
{"text": "10.1186/1472 - 6963 - 12 - 385 View Article PubMed Central PubMed .Thornton A , Lee P : Publication bias in meta - analysis : its causes and consequences .", "label": "", "metadata": {}, "score": "81.18274"}
{"text": "Percentage of Participants With ALT Normalization at Weeks 144 , 192 , 240 , 288 , 336 , and 384 [ Time Frame : Baseline ; Weeks 144 , 192 , 240 , 288 , 336 , and 384 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "81.91977"}
{"text": "Quantitative variables were expressed as mean , and categorical variables were presented as counts and percentages , and HBV DNA levels were presented as log transformation .", "label": "", "metadata": {}, "score": "81.96175"}
{"text": "Inclusion and exclusion criteria .The following inclusion criteria were included : ( 1 ) randomized controls , prospective case - controls , cohort study designs .", "label": "", "metadata": {}, "score": "82.34303"}
{"text": "Serum bone - specific alkaline phosphatase ( BAP ) is the most commonly used bone disease marker in hemodialyzed patients [ 19 ] .Serum BAP levels increase gradually in osteomalacia secondary to the administration of ADV , without increase in serum creatinine concentration [ 17 , 18 ] .", "label": "", "metadata": {}, "score": "83.34715"}
{"text": "Periodic measurement of serum BAP may be helpful in the early detection of osteomalacia in the absence of elevation of serum creatinine concentration .Conclusions .", "label": "", "metadata": {}, "score": "83.4734"}
{"text": "Nucleos(t)ide analogs(NAS)have become the mainstay of CHB treatment mainly due to their profound viral suppressive effects , the convenience of single daily dosing and relative lack of significant side effects .", "label": "", "metadata": {}, "score": "83.69394"}
{"text": "Serum creatinine(Scr ) .Declarations .Acknowledgements .Competing interests .The authors declare that they have no competing interests .Authors ' contributions .HP and RH conceived the study , provided fund supporting and revised the manuscript critically for important content .", "label": "", "metadata": {}, "score": "84.436844"}
{"text": "Thailand .HIV-1 RNA [ units : log10 copies / mL ] Mean ( Standard Deviation ) .CD4 + T - cell count [ units : cells / mm^3 ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "84.46559"}
{"text": "Gender .Both .Ages .18 Years to 69 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "84.52603"}
{"text": "Literature search .We searched the following databases : PubMed , Embase , Web of Science , The Cochrane Library , OVID , and CBM ( Chinese Biological Medical Literature ) until May 1 , 2013 .", "label": "", "metadata": {}, "score": "84.58377"}
{"text": "We initially identified 1753 potentially eligible citations .1739 redundant publications , reviews , and meta - analysis were excluded .After referring to full text , seven studies did not satisfy the inclusion criteria and were removed from consideration .", "label": "", "metadata": {}, "score": "85.41676"}
{"text": "10.1016/j.jhep.2008.01.027 View Article PubMed .Antimicrob Agents Chemother 2004 , 48 : 3498 - 3507 .10.1128/AAC.48.9.3498 - 3507.2004 View Article PubMed Central PubMed .", "label": "", "metadata": {}, "score": "85.74754"}
{"text": "In addition , many studies were conducted in China resulting in regional and language bias .Finally , there were only a few studies and the sample size was small .", "label": "", "metadata": {}, "score": "85.877655"}
{"text": "Interventions : .Drug : Tenofovir .Drug : Entecavir .Active Comparator : Tenofovir monotherapy .Tenofovir 300 mg / day orally .Intervention : Drug : Tenofovir .", "label": "", "metadata": {}, "score": "85.90892"}
{"text": "Other Markers in Serum and Urine .All statistical analyses were performed using STATISTICA for Windows version 6 ( StatSoft , Oklahoma , USA ) .", "label": "", "metadata": {}, "score": "85.94837"}
{"text": "Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48 [ Time Frame : Baseline ; Week 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "86.65589"}
{"text": "Competing interests .The authors declare that they have no competing interests .Authors ' contributions .MDJ conceived the study and revised the manuscript critically for important intellectual content .", "label": "", "metadata": {}, "score": "86.705795"}
{"text": "There was no significant difference between the ADV and non - ADV groups in the concentration of serum alkaline phosphatase ( ALP ) isoenzyme 2 , which is liver specific ; however , serum BAP concentration was significantly higher in the ADV group than in the non - ADV group ( .", "label": "", "metadata": {}, "score": "86.8491"}
{"text": "Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight Our site uses cookies to improve your experience .", "label": "", "metadata": {}, "score": "87.53502"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00142298 .Hepatitis Hepatitis B Hepatitis B , Chronic Hepatitis , Chronic DNA Virus Infections Digestive System Diseases Hepadnaviridae Infections Hepatitis , Viral , Human Liver Diseases .", "label": "", "metadata": {}, "score": "87.79939"}
{"text": "506 - 512 , 1996 .View at Google Scholar \u00b7 View at Scopus .J. A. Whitworth , \" 2003 World Health Organization ( WHO)/International Society of Hypertension ( ISH ) statement on management of hypertension , \" Journal of Hypertension , vol .", "label": "", "metadata": {}, "score": "88.27019"}
{"text": "The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system , and ranges from 0 ( best ) to 14 ( worst ) .", "label": "", "metadata": {}, "score": "89.43059"}
{"text": "Authors ' information .Fen Liu is a master 's degree candidate with a major of infectious disease medicine in The Second Affiliated Hospital of Chongqing Medical University , Chongqing , Chongqing , China .", "label": "", "metadata": {}, "score": "89.594315"}
{"text": "The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14 ; the Knodell fibrosis domain score ranges from 0 to 4 .", "label": "", "metadata": {}, "score": "89.77411"}
{"text": "Declarations .Acknowledgements .This work was supported by the National Natural Science Foundation of China ( No . 30972584 and No . 30930082 ) , National Science and Technology Major Project of China ( No . 2008ZX10002 - 006 ) and the Program for Changjiang Scholars and Innovative Research Team in University ( No .", "label": "", "metadata": {}, "score": "89.7897"}
{"text": "10.1002/jmv.23440 View Article PubMed .10.1016/j.jhep.2007.12.026 View Article PubMed .Hepatol Int 2011 , 5 : 671 - 676 .10.1007/s12072 - 010 - 9243-x View Article PubMed Central PubMed .", "label": "", "metadata": {}, "score": "91.05956"}
{"text": "The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system , which ranges from 0 ( best ) to 14 ( worst ) .", "label": "", "metadata": {}, "score": "91.31935"}
{"text": "The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system , which ranges from 0 ( best ) to 14 ( worst ) .", "label": "", "metadata": {}, "score": "91.31935"}
{"text": "PubMed View Article .PubMed View Article .PubMed View Article .Hepatology 2009 , 49 ( 1 ) : 72 - 79 .PubMed View Article .", "label": "", "metadata": {}, "score": "91.58533"}
{"text": "Department of Infectious Diseases , Institute for Viral Hepatitis , Key Laboratory of Molecular Biology for Infectious Diseases , Ministry of Education , The Second Affiliated Hospital of Chongqing Medical University .", "label": "", "metadata": {}, "score": "92.116516"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "92.204056"}
{"text": "Competing interests .The funding source had no influence on study design , in the collection , analysis , interpretation of the data , writing of the manuscript , or in the decision to submit the manuscript for publication .", "label": "", "metadata": {}, "score": "93.38402"}
{"text": "J Korean Med Sci 2005 ; 20 : 821 - 828 .10 Fung SK , Chae HB , Fontana RJ , Conjeevaram H , Marrero J , Oberhelman K , et al .", "label": "", "metadata": {}, "score": "93.8576"}
{"text": "By continuing to browse this site you agree to us using cookies as described in About Cookies .If you ca n't find a tool you 're looking for , please click the link at the top of the page to \" Go to old article view \" .", "label": "", "metadata": {}, "score": "94.62178"}
{"text": "The Ishak score measures the degree of liver fibrosis ( scarring ) caused by chronic necroinflammation ( inflammation leading to cell death ) and ranges from 0 ( best ) to 6 ( worst ) .", "label": "", "metadata": {}, "score": "94.91722"}
{"text": "24 , no . 3 , pp .429 - 435 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Abstract .", "label": "", "metadata": {}, "score": "96.255585"}
{"text": "Coinfection with hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) , or hepatitis D virus ( HDV ) .Significant renal , cardiovascular , pulmonary , or neurological disease .", "label": "", "metadata": {}, "score": "96.944016"}
{"text": "Estimated Completion Date .February 2018 .Primary Completion Date .June 2014 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .", "label": "", "metadata": {}, "score": "97.261215"}
{"text": "Further , serum BAP concentration increased before serum phosphate decreased ; this finding may indicate that serum phosphate was being released from the bones , even though it was being lost through the kidneys .", "label": "", "metadata": {}, "score": "102.387375"}
{"text": "For cohorts , the quality of studies was assessed by the Newcastle - Ottawa Scale ( NOS ) based on the following indicators : selection of cohorts , comparability of cohorts and assessment of the outcomes .", "label": "", "metadata": {}, "score": "103.35498"}
{"text": "View Article PubMed .Ann Intern Med 2007 , 147 : 745 - 754 .10.7326/0003 - 4819 - 147 - 11 - 200712040 - 00183 View Article PubMed .", "label": "", "metadata": {}, "score": "104.90089"}
{"text": "The others had scores of 9 .Discrepancies were resolved with the assistance of an arbiter ( Peng Hu ) when necessary .Statistical analysis .", "label": "", "metadata": {}, "score": "105.685745"}
{"text": "Discrepancies were resolved with the assistance of an arbiter ( Peng Hu ) when necessary .Study quality .Discrepancies were resolved with the assistance of an arbiter ( Peng Hu ) when necessary .", "label": "", "metadata": {}, "score": "115.36515"}
{"text": "10.1016/S0895 - 4356(99)00161 - 4 View Article PubMed .Copyright .\u00a9 Liu et al . ; licensee BioMed Central Ltd. 2014 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "119.265335"}
{"text": "Received 11 June 2013 ; Revised 6 August 2013 ; Accepted 7 August 2013 .Copyright \u00a9 2013 Hiroshi Abe et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "132.01317"}
{"text": "United States , Australia , Bulgaria , Canada , Czech Republic , France , Germany , Greece , Italy , Netherlands , New Zealand , Poland , Spain , Turkey , United Kingdom", "label": "", "metadata": {}, "score": "139.61562"}
